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Abstract 
Background: Seeking direct patient input to inform health care decision making is vital to 
maintain and improve quality of life among those with chronic diseases. The initiative to 
incorporate and understand patient-reported outcomes (PROs) in clinical practice has recently 
increased in the field of ophthalmology to improve glaucoma management.  
Objective: To identify the most important predictor variables for four PROs: social support and 
community integration, presence of depressive symptoms, vision-related quality of life (VRQoL) 
and preference-based Health-Related quality of life (HRQoL).  
Methods: A cross-sectional study was conducted among glaucoma and glaucoma suspect 
patients in London, Ontario (n = 250). Data were collected through medical chart reviews and 
face-to-face interviews. The four PROs were measured using validated tools. Linear, logistic and 
stepwise regression models, and classification and regression trees were built using candidate 
variables. Through leave-one-out cross-validation, the predictive performance of each model was 
assessed with mean absolute error, standard error and standard deviation.  
Results: Use of mobility aids, best corrected visual acuity (BCVA), income and living 
arrangements were common predictor variables identified for VRQoL, and social support and 
community integration. Use of mobility aids was also identified for the presence of depressive 
symptoms, and BCVA for preference-based HRQoL. 
Conclusion: The identified predictor variables suggest that routinely collected variables in 
ophthalmic practice alone are not sufficient to understand PROs. Our research study presents 
evidence that may allow better management of glaucoma through guidance of how to integrate 
patient-centered approach to care with the traditional clinical approach.  
Keywords 
Glaucoma, patient-reported outcome, social support, community integration, depressive 
symptoms, vision-related quality of life, preference-based health-related quality of life 
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Chapter 1  
1 Introduction 
Glaucoma is a disease of the nerve that connects the eye to the brain. It is the most common 
cause of irreversible blindness worldwide and its cause remains unknown1. In 2002, glaucoma 
accounted for about 12.3% of the 37 million people who were blind world-wide2. Vision loss is 
the most frequently feared disability for Canadians and has one of the highest direct health care 
costs3. Globally, the direct cost of vision loss in 2010 was $2.3 trillion4. In the United States, it 
was estimated that 17.8%, of the direct costs from ocular diseases, was due to patients with 
glaucoma2. In 2007, the financial burden of vision loss in Canada was estimated to be $15.8 
billion and by 2032, vision loss is expected to cost Canadians about $30.3 billion 3.  
 
Public spending on healthcare is one of the largest government expenditures and health care 
costs continue to escalate, especially with the elderly Canadian population expected to represent 
about 25% of the population by 20365. Given the cost constraints, policy decisions to deliver 
quality health care, optimal clinical practice and a patient-centered health care system must be 
supported by evidence that incorporates patient-reported outcomes (PROs)6. The diagnosis and 
progression of glaucoma is accompanied by negative consequences on health outcomes directly 
affecting the patient7. Thus, in addition to clinical characteristics of glaucoma, expanded 
elements of health care such as the economic burden, patient characteristics and PROs also need 
to be measured for glaucoma management. 
 
Although glaucoma cannot be cured, the progression can be delayed with treatment. Glaucoma 
impacts the patient in various ways, such as psychological effects, functional disabilities, 
treatment side effects, treatment costs, and inconvenience of treatments8. In today’s healthcare 
climate, patients with glaucoma need to be managed efficiently in a comprehensive manner, 
rather than a limited scope determined solely by the clinical symptoms of the eye. Quaranta et al. 
(2016) presented a review of the quality of life (QoL) literature in glaucoma, which suggested 
that patients with glaucoma may be at a higher risk for a lower QoL, including the burden from 
side effects and costs of treatment9. Since, glaucoma is a multifactorial disease and requires 
multidimensional management, understanding the factors associated with different QoL domains 
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is necessary for developing effective interventions10. Current treatment options for glaucoma 
include topical and oral ophthalmic medications, laser and incisional surgical treatments, all  
which focus on prevention of disease progression by reducing intraocular pressure (IOP)9. Some 
patients may not require initiation of treatment upon first assessment, but rather may be routinely 
observed until the risk of progression is sufficient to warrant intervention. The primary goal is to 
preserve the patients’ QoL by preventing functional visual impairment and minimizing the side 
effects and complications of glaucoma treatment9. Thus, analyzing the relationship between 
clinical characteristics, individual characteristics and various QoL domains will provide a more 
comprehensive understanding of the patient to assist with glaucoma management. Glaucoma 
management entails more than just the correct diagnosis of the disease, because it requires 
lifelong treatment and assessment11. To effectively treat and manage the patient, a 
comprehensive understanding of the patient is required. This will allow for patients to be more 
involved in their care, understand the disease progression, improve their overall health and 
reduce avoidable health care costs11.  
 
In ophthalmic practice, disease management outcomes have been mainly assessed with clinical 
characteristics as opposed to PRO measures12. Over the recent years, the need to understand the 
fundamental disease processes, appreciate individual differences, preserve high level of visual 
function while improving the quality of care has enticed tremendous interest in studying PROs 
among glaucoma patients9,13–18. PROs are fundamental to involving patients in their clinical 
decision-making process and understanding patient experiences, as we move from a “disease-
based” to “patient-centered” model of care12,13. This is especially important in chronic diseases 
that require compliance to lifelong management. Linking clinical and demographic variables to 
PROs is important for understanding the associations between variables within a complex 
construct such as Health-Related quality of life (HRQoL). Understanding this association is 
important to describe the patient’s experiences in response to their disease management and 
treatment. Overall, it is an improved method of assessing the patients’ health status19. Thus, in 
addition to expert opinions and review of relevant literature, this thesis presents the adaptation of 
a model that conceptualizes the associations of clinical variables to HRQoL measures, proposed 
by Wilson and Cleary in 1995 (Figures 2-1 and 2-2)19. 
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Improving health among glaucoma patients starts with understanding health outcomes as 
perceived by the patient (i.e., PROs). The importance has recently increased due to the creation 
of formalized programs by governments which seek direct patient input into health care decision 
making policies – Food and Drug Administration (FDA) and Centers of Excellence in 
Regulatory Science and Innovation (CERSI) project20, and Ontario Clinical Expert Panel for the 
Glaucoma Quality Standard (May 2017). While the need to integrate PROs in glaucoma 
management and treatment is apparent, it is routinely not used by ophthalmologists21. The  
“Canadian Ophthalmological Society evidence-based clinical practice guidelines for the 
management of glaucoma in the adult eye” does not specify the PRO instruments available, thus 
ophthalmologists may not be aware of which instruments are relevant to their patients 22. There 
are several instruments available to assess PROs, therefore determining which one to use among 
glaucoma patients can be a challenge.  
 
Developing a predictive model for PROs may improve clinical decision-making by providing 
guidance as to how to incorporate PROs in ophthalmic practice and identifying the need for 
additional support and/or resources. Machine learning techniques are used to automatically 
detect patterns from a given dataset and in the clinical decision-making process23. Previous 
studies of glaucoma have not performed machine learning techniques to identify which variables 
are predictive of PROs. The first step to building a predictive model, is to identify important 
clinical and demographic variables that are strongly associated with a specific PRO. This is the 
goal of our research study. The identified clinical and demographic variables will be used to 
build a predictive model aimed to estimate PROs. The developed model can be used to identify 
patients at risk of poor PROs and determine clinical interventions as per the patients’ needs. This 
resulting predictive model will further need to be assessed for accuracy in various populations in 
order to be used as a validated tool. The predictive model can also be beneficial for research 
purposes, as it will allow researchers, health economists, policy makers and health care 
administrators to efficiently estimate PROs at a population level to provide evidence to guide 
administrators on health budget allocation for chronic diseases such as glaucoma.  
 
 
  
 
 
4 
Chapter 2  
2 Literature Review 
2.1 Background of Glaucoma  
Population based studies identified glaucoma as the main cause of irreversible world-wide 
blindness24. Glaucoma is a chronic neuro-degenerative disorder of the optic nerve that is 
characterized by progressive structural and functional loss, resulting in vision loss and 
blindness24,25. It is characterized by the degeneration of retinal ganglion cells and their axons, 
which results in visual impairment and optic nerve damage 26. Retinal ganglion cells receive 
visual information and the optic nerve is responsible for carrying the visual information from the 
eye to the brain26. Retinal ganglion cell death and optic nerve fiber loss are among the most 
important changes that characterize the glaucoma diagnosis27. Initial changes to the optic nerve 
are asymptomatic28.  
Glaucoma is detected through a comprehensive eye examination that includes assessment of the 
status of the optic nerve and retina, measurement of the best corrected visual acuity (BCVA) at 
various distances, intraocular pressure (IOP), central corneal thickness (CCT), visual field and 
assessment of the anatomical angle between the cornea and iris29. Some of the major risk factors 
for glaucoma that have been identified include: elevated IOP, increased cup-to-disc ratio (CDR), 
decreased CCT, pseudoexfoliation syndrome, genetic factors and older age24. IOP is the only 
currently known treatable risk factor, which is reduced using medication, laser and/or traditional 
surgery30. There are also potential risk factors that remain unidentified.  
In a healthy eye, constant eye pressure is maintained, whereas in an eye with glaucoma the 
damage occurs when fluid builds up and increases the pressure in the eye31.  There is a subset of 
patients who experience glaucomatous optic neuropathy at normal IOPs which further highlights 
the complexity of the disease and likely contributes to the fact that the etiology remains 
unknown32. Glaucoma patients begin losing their peripheral vision which progresses to central 
visual loss followed by blindness if left untreated. Most glaucoma diagnoses are based on 
progressive structural and functional optic nerve damage; however there is currently no 
definitive standard for diagnosis31. Since glaucoma is not curable and is irreversible, the goal of 
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glaucoma management and treatment is to minimize its progression and to preserve the patients’ 
HRQoL. Glaucoma treatment starts with establishing the type of glaucoma diagnosis33. 
2.2 Types of Glaucoma 
There are several types of glaucoma that have been identified based on etiology of the 
underlying disease and mechanism of abnormality in the eye. The two main types of glaucoma 
include open-angle and angle-closure. 
Primary Open-angle glaucoma (POAG) is the most common type of glaucoma 
characterized by a functional blockage of the drainage canal34,35. Because of the 
blockage, fluid accumulates and causes increased pressure in the eye and damage to the 
optic nerve. 
Angle-closure glaucoma (ACG) requires immediate medical attention when it occurs 
acutely, because the entrance to the drainage canal becomes anatomically very narrow or 
completely closed35. Thus, the pressure can rise rapidly and cause extreme pain to the 
patient and sudden vision loss. 
Normal tension glaucoma (NTG) is a type of glaucoma in which the optic nerve is 
damaged without increased pressure in the eye34. It is unclear as to why the optic nerve is 
susceptible to damage, even when the eye pressure is relatively normal.  
Secondary glaucoma develops secondary to other conditions such as diabetes, eye 
trauma or inflammation in the eye, in which the additional factor causes elevated IOP34. 
The most common types of secondary glaucoma include: pseudoexfoliative glaucoma, 
pigmentary glaucoma and neovascular glaucoma.  
Glaucoma suspects are patients who have some, but not all, of the featured 
characteristics of glaucoma. Glaucoma suspects may have normal pressure in the eye, but 
their optic nerve or visual field findings suggest a risk of developing glaucoma34. In some 
cases, patients may have elevated eye pressure (ocular hypertension) but show no signs of 
optical nerve damage. Patients with ocular hypertension are at greater risk for developing 
glaucoma compared to age-matched normal subjects34. Glaucoma suspects can be those 
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that have risk factors for future development of glaucoma or those who suffer early 
glaucoma damage that cannot be differentiated from normal damage due to aging36. 
Depending upon the extent of the risk factor profile, glaucoma suspects may or may not 
receive treatment.  
2.3 Epidemiology of Glaucoma  
2.3.1 Prevalence of Glaucoma  
Most of the epidemiological studies in glaucoma pertain specifically to POAG, because most 
studies were conducted in North America and Europe, where the most common form of 
glaucoma is POAG37. Several studies have attempted to determine the prevalence of glaucoma 
since the 1920s, however the criteria for diagnosing glaucoma have changed since then and 
continue to evolve, the latter primarily based on advancements in diagnostic technologies38–40. It 
was not until 1938, when gonioscopy was introduced, that open-angle and closed-angle 
glaucoma were differentiated and glaucoma was not merely based upon the elevation of IOP38.  
Glaucoma is the second leading causes of global blindness and the leading cause of irreversible 
visual loss that disproportionately affects people residing in Asia and Africa2,41. In 2010, it was 
estimated that about 60.5 million people globally were affected by glaucoma and this number is 
expected to increase to 79.6 million by 2020 and 111.8 million by 204041,42. Data from 
population based studies reported the mean prevalence for POAG worldwide in 2010 as 1.96% 
and 59.1% of all people with glaucoma were female42.  Although there have been a number of 
prevalence surveys conducted in various racial and ethnic groups worldwide, caution must be 
taken in interpreting these results as there exists great variability in the methodology, quality of 
the data collected and variability among glaucoma diagnostic criteria43. 
POAG is the most common form of glaucoma, accounting for about 19% of all blindness among 
African Americans compared to only 6% of Caucasians44. Africans have a higher prevalence of 
POAG than do Europeans or Asians, and ACG is most common in Asians38,43. African 
Americans are 15 times more likely to be visually impaired and six to eight times more likely to 
be blind from glaucoma than Caucasians45. In a systematic review and meta-analysis that 
included population-based studies published up until March 2013, the global prevalence of 
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glaucoma was reported to be 3.54% for a population between 40 to 80 years of age41. Prevalence 
increases proportionally with age. Those older than 70 years of age have an “average estimated 
prevalence of 6% in white populations, 16% in black populations and 3% in Asian 
populations”38. Thus, glaucoma is of great concern due to the current aging population. It is also 
important to note that the rate of undiagnosed glaucoma is fairly high, since glaucoma is often 
asymptomatic until the very advanced stage at which point irreversible functional blindness is 
likely41. 
Population based studies for determining disease prevalence are crucial, since there exist 
regional differences in the prevalence of different types of glaucoma46. However, such studies 
are minimal in Canada. In 1965, a screening survey of about 18,000 participants conducted in 
Scarborough, Ontario reported a glaucoma prevalence of 2.2%47. Analysis of self-reported data 
in 2002 to 2003, revealed that about 409 000 Canadians were diagnosed with glaucoma, of 
which 2.7% were above 40 years old and 11% were above 80 years old26. Then in 2005, another 
screening study on a high-risk population reported glaucoma in 7.2% of the participants49. In 
2007, based on Canada-wide health surveys, the prevalence of self-reported glaucoma was 2.7% 
among Canadians older than 40 years of age50. Further, in a 2008-2009 cross-sectional study 
conducted in Toronto, Ontario consisting of Canadians 50 years of age or older, reported 7.5% of 
the participants having glaucoma and the prevalence of undetected glaucoma was 3.9%50. It is 
estimated that about 50% of people with glaucoma are not aware that they have the disease and 
therefore are not receiving glaucoma treatment51. Since glaucoma is relatively asymptomatic in 
the early stages, the statistics obtained from health surveys are likely underestimated.  
2.3.2     Incidence of Glaucoma  
Very few incidence studies of glaucoma have been reported. Since POAG is initially an 
asymptomatic disease, patients may not seek treatment until the later stages. Effective screening 
for glaucoma continues to be a global health problem52. In the earlier stages, it can be 
challenging to identify the precise stage at which a glaucoma suspect progresses to glaucoma. 
Difficulties with staging the glaucoma diagnosis and the need to follow up with patients is a 
challenge in determining the incidence of glaucoma37.  
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The first reliable data were collected in a 1989 longitudinal study, in Sweden, among a 
population of 55 to 69 years of age, which reported the estimated incidence rate to be 0.25% in a 
10 year follow-up period 28. In a more recent study the four-year incidence of POAG in Barbados 
was reported to be 2.2%, and incidence rates increased from 1.2% at 40 to 49 years of age to 
4.2% at 70 years or greater38. Among people in Netherlands, the rates increased from 1% at age 
60 to 3% at age 8038. The incidence rate over time in a Caucasian population increased from 0.08 
at 40 years of age to 1.46 at 80 years of age37. Thus, the incidence of glaucoma increases with 
age. 
2.3.3     Risk Factors for Developing Glaucoma  
When assessing the risk factors for a disease, large population-based studies are more 
representative than hospital-based studies, due to the selection bias among hospital patients, 
which can lead to an overestimation of certain potential risk factors for developing glaucoma37. 
The main risk factors that have been examined in population-based studies include: demographic 
factors such as age, gender and race; ocular factors such as IOP, appearance of the optic nerve, 
myopia, hypermetropia, presence of exfoliation, pigment dispersion, inflammation, narrow 
angles and history of trauma; systemic factors such as diabetes, hypertension and vasospastic 
disorder; genetic factors and other proposed lifestyle risk factors such as cigarette smoking and 
alcohol intake37. 
2.4 Glaucoma Treatment and Management 
There is always a trade-off involved when making treatment decisions. In the case of glaucoma 
treatment, patients make a treatment decision based on the trade-off between avoidance of 
blindness and treatment side effects and complications53. Understanding HRQoL in glaucoma 
patients could provide insight into the extent of visual disability and side effects of the treatments 
from the perspective of the patient9. It is both ideal and important to consider the patient’s 
perspective and their priorities when developing a treatment plan27. This is further punctuated by 
the fact that glaucoma management has been plagued by well documented poor patient 
compliance to medical therapy11,54,55. Since glaucoma is a progressive disease and is incurable, 
understanding how glaucoma affects PROs can influence medical decision making to optimize 
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treatment strategies and adherence, develop rehabilitation programs, allocate necessary resources 
and ultimately improve patient-physician relationships7.  
Glaucoma treatments include medications, laser and surgical interventions, which can influence 
the patient’s HRQoL, by relieving symptoms but also by inducing side-effects and 
complications. As POAG tends to be asymptomatic in the early to moderate stages, patients often 
perceive the treatments as being more negative than the disease itself. In a cross-sectional study 
among POAG and ocular hypertension (OHT) patients, in addition to clinical characteristics, 
medication side effects and glaucoma surgery also affected HRQoL56. Commonly reported side 
effects from topical and systemic medications include burning, tearing, blurred vision, stinging 
and redness57. In addition, the complexity of treatment regimen; taking multiple doses; having to 
travel with the medications; and difficulties in administering medications can negatively 
influence HRQoL57–59. In a cross-sectional study, the results showed that difficulty with the use 
of medication was the only factor that was negatively associated with HRQoL scores59. Other 
studies have indicated that the greater number of doses per day and use of additional medications 
correlated with noncompliance57,59,60. The daily use of medication may stress the burden of 
having an incurable disease and interfere with their daily life. Patients who are satisfied with 
their treatment have a greater adherence to their treatment, more likely to be involved in their 
care and use resources appropriately58,59. Thygesen et al. (2008) reported that the treatment with 
greater cost savings was found in the social care sector (i.e., assistance with daily activities) as 
opposed to the health care sector (i.e., medical treatment)61. Majority of the costs in terms of 
glaucoma management were found to be medication-related, with the financial burden increasing 
with advanced glaucoma severity62. 
The Collaborative Initial Glaucoma Treatment Study (CIGTS) randomized newly diagnosed 
POAG patients to treatment with medications or trabeculectomy. Although there were very few 
between-group differences in outcomes, patients in the trabeculectomy group reported more 
difficulties with visual acuity related activities58. After the five-year follow-up period, patients 
reported a reduction of symptom frequency and burden in both treatment groups58. A cross-
sectional study with Brazilian glaucoma patients found that surgery was a predictor of poor 
HRQoL scores in patients only with early stage glaucoma60. A cross-sectional study 
investigating the HRQoL among three groups: medical treatment, surgical treatment and 
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combination of medical and surgical treatment found no difference between the HRQoL scores 
among patients in the surgical or medical group60. The results also suggest that in the surgical 
group, glaucoma had less of an impact on their daily lives, although patients were still concerned 
about the progression of glaucoma60.  
Glaucoma is a chronic disease that affects many aspects of a patient’s life; thus, success of 
glaucoma management should not be measured only by objective clinical parameters such as 
IOP. This is a key factor when considering the goal of the various therapies. For example, a low 
risk surgical intervention that reduces the dependency on medications may be far more beneficial 
to a patient’s QoL without any additional effects on IOP reduction. Many patients with glaucoma 
are combating other concurrent comorbidities requiring treatment that could influence their 
compliance and satisfaction. 
Optimal treatment and management should incorporate objective measures of the patient’s visual 
function and glaucoma severity, as well as the subjective measure of the likely PROs under 
different possible treatment options63. In terms of a cost-effective treatment, the goal is to 
achieve a better health outcome at a lower cost. Thus, understanding the impact of glaucoma, 
identifying individual needs and assessing the effectiveness of treatment options is crucial to 
glaucoma management.  
2.5 Health Outcomes of Glaucoma 
Traditionally, health outcomes were based on a biomedical model and objectively defined as 
mortality and morbidity associated with biological functioning13. This approach does not 
consider the patients’ perception and experiences of their current health state. More recently, 
health outcomes are being viewed in terms of a biopsychosocial model, which incorporates a 
more holistic view of the patient and includes psychological and social factors64. Health 
outcomes discussed in our research study include clinical outcomes and PROs. 
2.5.1 Clinical Outcomes 
Clinical outcomes are outcomes that are not reported by the patient and are used by clinicians to 
diagnose and manage the progression of the disease13. There is great variability in the clinical 
presentation of patients with glaucoma27. Clinical outcomes are identified through a 
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comprehensive eye exam which include the following assessments: best corrected visual acuity 
(BCVA), gonioscopy, tonometry, corneal pachymetry, perimetry, visual acuity test and optic 
nerve and retinal nerve fiber layer imaging 65. All components of the eye exam are used to 
diagnosis and determine the staging of glaucoma (Section 4.4.2.5 defines the stages of 
glaucoma). Clinical outcomes vary depending on the type and severity of glaucoma30. 
2.5.1.1 Gonioscopy 
Gonioscopy is a technique used to assess the configuration of the anterior segment angle. This is 
located between the cornea and the iris66. Goinioscopy permits the determination of whether the 
angle is anatomically open or closed66. 
2.5.1.2 Tonometry 
Tonometry measures the IOP using a tonometer27. Although, elevated IOP levels is a prominent 
clinical presentation that is strongly associated with the development of glaucoma, there are 
patients with elevated IOP levels (> 21 mm Hg) that do not develop glaucoma and other patients 
who are diagnosed with glaucoma who have a normal IOP level (£ 21 mm Hg)26,67.  
2.5.1.3 Corneal Pachymetry 
Pachymetry determines the corneal thickness. Normal CCT ranges between 545 and 550 µm and 
is race dependent66. Thin corneas (< 500 µm) are a risk factor for progression of glaucoma, while 
thicker corneas (> 600 µm) are relatively protective30.  
2.5.1.4 Perimetry 
A perimetric test, also known as visual field test,  is used to quantify the level and rate of 
functional visual impairment and is complemented by image-based structural measurements of 
the optic disc, retinal nerve fiber layer and ganglion cells68.  Visual field loss is a sign of 
glaucomatous damage and is a crucial measurement for management of the disease68. Mean 
deviation (MD) is the overall deviation from normal values (0 dB to -2 dB) of the hill of vision 
which defines the visual field69. 
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Glaucoma at a later stage is generally more straightforward to diagnosis; however for glaucoma 
suspects, who present with normal visual field and elevated IOP, they usually require repeat 
perimetric tests over time68. With patients already diagnosed with glaucoma, perimetric tests play 
a key role in managing the disease to determine if the treatment is adequate or if a change is 
required68. 
2.5.1.5 Visual Acuity Test 
The Snellen chart is an eye chart typically used to measure central visual acuity, which is a 
measure of how well a patient sees at various distances (i.e., sharpness of vision)27. Visual acuity 
is scored as a set of two numbers known as the Snellen fraction70. For example, usually 20/20 is 
defined as normal, where the top number represents the distance from which the test is conducted 
and the bottom number represents the distance that the typical healthy eye can see the letters on a 
certain line of the eye chart70. The loss or abnormality of visual functions leads to visual 
impairment71.   
2.5.1.6 Optic Nerve and Retinal Nerve Fiber Layer Imaging 
Dilated eye examination is performed to examine the optic nerve and retina for signs of 
damage66. Specifically, the imaging tests used are Heidelberg Retinal Tomography (HRT), which 
provides a quantitative evaluation of the topography of the optic nerve and/or Optical Coherence 
Tomography (OCT) which measures the retinal nerve fiber thickness within the retina72. 
Optic nerve damage produces thinning and decreased visibility of the retinal fiber layer (RNFL) 
35. Due to the way the retinal ganglion cells enter the optic nerve, the vertical cup-to-disc ratio is 
a useful clinical measurement of the structural status of the optic nerve30. Typically, glaucoma is 
associated with a progressively increasing cup-to-disc ratio, due to the degeneration of the retinal 
ganglion cells30. Normal cup-to-disc ratio is about 0.3 (ranging between 0.1 and 0.8)67.  
2.5.2 Symptoms  
Symptoms are associated with the disease itself and the treatment effect73. Glaucoma progression 
can be asymptomatic in the early to moderate stages of the open angle disease27. Elevated IOP 
usually raises concern about the risk of glaucoma69. Pain is experienced by the patient when IOP 
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rises rapidly69. Visual impairment is the most noticeable symptom of glaucoma, but this is 
typically not experienced by the patient until the later stages of the disease69. Glaucoma usually 
develops slowly with very minimal initial symptoms; however, in some patients the rate of loss 
can be relatively rapid, depending upon several factors including the stage of the disease at the 
time of diagnosis74. Thus, it is important to routinely examine glaucoma suspects on a regular 
basis66. A key point is that the damage is irreversible with no known treatments once it has 
occurred. 
2.5.3 Patient-Reported Outcomes 
Clinical characteristics such as visual field and IOP are predominately the main outcomes 
assessed for clinical and research purposes despite neither defining the disease. As these are not 
able to provide information on the well-being and experiences of the patient, there is a need to 
focus on assessing PROs. Patients with glaucoma experience visual impairment, activity 
limitations, side effects of treatment, as well as effects on general health, lifestyle and emotional 
well-being. In addition to the medical problem, these patients experience social, economic and 
psychological problems. Thus, multidisciplinary approaches to research are needed to understand 
the biological, psychological and sociological factors influencing health-related outcomes as 
perceived by the patient. Understanding how glaucoma affects the patients’ daily activities as 
well as obtaining a perspective on the effects of disease progression and treatment are important 
in a patient-centered comprehensive approach to glaucoma management.  
PROs are needed to assess health outcomes from the patients’ perspective. PROs are able to 
address the patients’ vision-specific functional loss affecting different domains of their life and 
overall satisfaction of the patient’s health state23. PROs are subjective measures reflecting patient 
experiences, perceptions, symptoms, functional status or other domains influencing HRQoL, in 
terms of their health condition75. PROs represent what is important to the patient as it relates to 
the management and treatment of the disease75. Hence, PROs can help improve patient 
knowledge, identify issues and provide insights that influence glaucoma management76.  
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2.5.3.1 Quality of Life and Health-Related Quality of Life 
QoL and HRQoL are generic health outcome measures, which are often used interchangeably. 
Although QoL and HRQoL capture the subjective health perception of the patient, they each 
provide different information77. QoL is defined as a broad concept which encompasses all 
aspects of life such as family circumstances, finance, living arrangement and job satisfaction77. 
QoL is defined in the context of the patients’ culture and values76. On the other hand,  HRQoL is 
a component of QoL that is focused on the individuals’ perspective of their own health state as it 
relates to their overall functioning and well-being in terms of physical function, social and 
psychological factors77. HRQoL is usually a measure of self-perceived health status, depicting 
how health affects QoL or the utility associated with different health states77.  
Although the ocular damage due to glaucoma is initially asymptomatic, the patients’ HRQoL can 
be affected as soon as the diagnosis is made and/or the early damage and its treatment cause 
effects other than diminished central acuity. One of the very first studies to understand HRQoL 
in glaucoma patients in 1997, found that visual function impairment was correlated with 
peripheral vision, distance activities and vision-specific dependency78. Research across different 
HRQoL domains is important in order to provide insight to the aspects of daily living that are 
negatively affected by glaucoma76. Poor HRQoL in glaucoma patients can be due to various 
reasons and can differ across various patient populations. Reasons for diminished HRQoL 
specifically among glaucoma patients include: stress of diagnosis, disease severity, functional 
loss due to vision loss, loss of independence, inconvenience of frequent treatment and its side 
effects, cost of treatment and regular appointments for monitoring the progression of glaucoma62. 
Literature supports that even the mere diagnosis of glaucoma can negatively affect HRQoL79. 
Glaucoma is a progressive disease, but the diagnosis of glaucoma can come as a surprise to many 
patients, since patients may attribute their vision loss to normal degradation with aging29. It is 
often shocking to patients that they already have moderate to advanced disease at the time of 
diagnosis80,81. Current literature suggests HRQoL is more affected by the way patients perceive 
their vision as opposed to the objective measurement of it9.  
Patients diagnosed with POAG reported lower HRQoL scores than patients with suspected 
glaucoma9. Another study which used the same HRQoL measure, but with a larger proportion of 
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patients with early stage glaucoma, reported that HRQoL scores were not greatly affected by 
visual acuity or visual function impairment9. Past studies also suggest that HRQoL scores tend to 
be worse in patients with more advanced stages of glaucoma and with concurrent 
comorbidities9,82.  In a cross-sectional study among POAG and OHT patients, the clinical 
characteristics that affected HRQoL were MD and visual acuity56. The findings also suggest a 
stronger impact of visual function loss in the better eye on HRQoL than visual function loss in 
the worse eye9,56. Evidence in the literature suggests that the worst HRQoL is associated with 
more severe glaucoma, however there still exists some evidence of worst HRQoL even in the 
early stages of glaucoma17. Generally, HRQoL scores are associated with visual function loss, 
visual acuity and number of years since glaucoma diagnosis9. Despite the variability in study 
methodology, several studies have reported significant relationships between visual impairment 
and HRQoL9,83. 
2.5.3.2 Functional Status and Well-being 
Health effects of glaucoma extend beyond the eye, as patients with glaucoma experience 
limitations to their functional status and well-being84,85. Clinical outcomes such as visual field 
and visual acuity loss, can limit the patients’ ability to be independent, productive, participate in 
society, perform daily activities, and impact social and emotional well-being85. Assessing 
functional status and well-being is important to inform rehabilitation care9.  
The World Health Organization (WHO) refers to disability as a broad term encompassing 
impairments, activity limitations and participation restrictions86. Patients with disabilities, such 
as visual impairment, require coordination of care among a multidisciplinary care team (i.e., 
optometrists, ophthalmologists, social workers and rehabilitation services). ‘Functional status’ 
and ‘health status’ are among other terms used in a similar context as QoL and HRQoL13. Health 
status is usually referred to the broader well-being of the patients in terms of disability54.  
Functional status assess the ability of the individual to perform social roles without any 
limitations and focuses on tasks such as activities of daily living77.  
Performing activities of daily living is often a problem in patients with visual impairment85,87. 
Visual impairment and progression to blindness, increases functional disability, dependency, 
accidents, depression, decline in physical and mental health9,76,87,88. Patients with bilateral visual 
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field loss have reported poor performance on mobility activities such as driving, in comparison 
to patients with unilateral visual field loss89. Progression of glaucoma can lead to vision-related 
disability, loss of visual acuity and blindness, thus patients experience problems associated with 
activities of daily living such as reading and driving24. Visually impaired individuals are at a 
higher risk for accidents, social withdrawal and depression9. Due to the loss of visual acuity in 
glaucoma patients, many report concern with activities requiring central and near vision and 
outdoor mobility9. Activities such as walking, reading, visibility at night and noticing objects 
through peripheral vision, have been reported to be major concerns45.  Patients with moderate to 
severe visual field loss, decreased contrast sensitivity and depth perception, report difficulties 
with driving and the need to discontinue or drive less frequently9. Tasks requiring central or near 
vision, outdoor mobility and driving are the most deteriorated activities of daily living among 
glaucoma patients76. Outdoor mobility restrictions was strongly correlated with the amount of 
visual field loss in the worse eye and those with visual impairment were more likely to report 
accidents and falls76. Such limitations to activities of daily living can lead to patients’ loss of 
independence and lower HRQoL. Glaucoma patients with moderate to severe visual field loss 
perform poorly on activities related to functional independence and level of mobility90.  
Glaucoma is a chronic condition that potentially can cause blindness91. Patients with glaucoma 
have reported high prevalence of anxiety and depression17. Driving limitations, fear of falling 
and imbalance also contribute to the relationship between glaucoma and depression17. In a case-
control study, anxiety and depression in POAG patients was reported to be significantly higher 
than the reference group92. In addition, increase in age and visual field loss were associated with 
depression92. Symptoms of depression were not found to be correlated with poor visual function; 
however, it was significantly correlated with the patient’s perception of their vision92. 
Glaucoma impacts a patient’s everyday functional abilities and each patient copes with the 
disease differently85. Understanding how glaucoma impacts the patient’s functional status and 
well-being, can assist with developing better management strategies for patients with glaucoma.   
2.6 Patient-Reported Outcome Instruments 
PRO instruments measure the patient’s health status such as HRQoL6. They are often self-
reported by the patient, but can also be completed by a proxy if the patient cannot self-report. 
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Assessing PROs to better manage the patient can be difficult using only one instrument, since 
patient tailored care requires a multidimensional understanding: personal factors, social 
relationships and participation, psychological well-being, physical health and health condition73. 
Although PROs are considered an important aspect of the patient’s health management and is 
collected in a standardized method in certain clinical practices, they are rarely collected in 
ophthalmic practice due to possible reasons such as: determining which PRO measure to use; 
lack of guidance on how to implement PRO measures routinely; difficulties with interpreting the 
results; time constraints;  and resource limitations63,73,93. Currently, there is a priority to 
incorporate the collection of PROs in ophthalmic practice, and a group of ophthalmology experts 
in Ontario are making an effort with government professionals to implement PRO assessment in 
routine practice –Ontario Clinical Expert Panel for the Glaucoma Quality Standard, 2017. Types 
of developed PRO instruments include: generic, disease-specific, dimension-specific and utility 
measures88.  
Among patients with glaucoma or at risk of glaucoma, previous studies assessed PROs using 
generic, glaucoma-specific, vision-specific, medication-specific and utility instruments95–97. 
These studies often used a combination of one generic and one vision-specific instrument. Our 
research study uses four different PRO instruments. There is a need for clear recommendations 
and guidance in clinical utilization of PRO instruments, given the plethora of PRO instruments 
available. 
2.6.1 Generic Instruments  
Generic tools were developed to provide the overall impact of the health condition and can be 
compared across various health conditions and are used to measure the general functional status 
of the patient 98.  Among generic instruments such as: EuroQol-5D (EQ-5D), the Sickness 
Impact Profile (SIP) and World Health Organization Quality of Life (WHOQOL), the most 
common generic tool used in glaucoma research is the Medical Outcomes Study Short Form-36 
(SF-36)17.  
The main advantage with the generic tool is that it can be used to compare across various 
populations, including populations without the health condition of interest13. These instruments 
provide a summary score across various dimensions such as physical and social functioning, 
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emotional and physical problems, role limitations and mental health13. However, because generic 
instruments assess broad dimensions, they may not be as directly relevant to specific populations 
and are potentially less responsive to clinically important changes13.  Studies using the generic 
instrument found that patients with glaucoma reported lower scores across all domains, 
compared to patients without glaucoma85,99.  
2.6.2 Glaucoma - Specific Instruments 
Glaucoma-specific instruments focus on the specific disease and reflects issues that are important 
to patients with glaucoma97. They are usually used to detect changes in the same population over 
time97.  Glaucoma-specific tools assess the symptoms, functional impairment, vision-related 
factors and extent to which glaucoma and treatment interfere with their health state94. They are 
clinically relevant, specific to the disease, but are rarely used in clinic, rather are mainly used as 
a research tool94. Overall, disease-specific instruments are more relevant and sensitive than 
generic instruments with regards to capturing changes in health status due to glaucoma 
management and treatment94. 
2.6.3 Vision - Specific Instruments  
Vision-specific instruments measure the functional impairment among patients with ocular 
conditions. They focus on visual ability, specific task performance and impact of visual 
impairment on the patient and their daily acitivites98. Commonly used vision-specific instruments 
include: the Visual Function Index (VF-14), National Eye Institute Visual Function 
Questionnaire (NEI VFQ), Activities of Daily Visual Scale (ADVS) and Visual Activities 
Questionnaire (VAQ)98. Vision-specific instruments were reported to be more sensitive than 
generic instruments when comparing patient with glaucoma to a reference group46,72,73. They 
were also found to be more correlated with clinical assessments46,72,73.  
2.6.4 Dimension - Specific Instruments 
Dimension-specific instruments are not popularly used in glaucoma research, thus their 
appropriateness as an outcome measure needs to be carefully considered and data on their 
psychometric properties are limited. Dimension-specific instruments are used when there is an 
interest in assessing a specific domain (i.e., social and emotional well-being). It is often more 
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detailed than the generic and disease-specific instruments13. Dimension-specific instruments 
discussed in this project include the Community Integration Questionnaire (CIQ) and the Patient 
Health Questionnaire - 9 (PHQ-9). 
2.6.5 Utility Measures 
Utility measures provide information on the patient’s preferences and values as it relates to their 
current health state13. Generally used techniques to obtain direct health utility values include:  
rating scales, standard gamble and time trade-off13. Utility values are useful for economic 
evaluations such as cost-utility analysis13. 
2.7 Selected Patient-Reported Outcomes 
Selection of appropriate PRO instruments depends on the purpose of the study and requires 
careful consideration of methodological issues such as: validity, reliability, feasibility and 
generalizability6,94. Several PRO tools in glaucoma have been developed to assess aspects of 
HRQoL. However, the challenge is deciding which of the many measurement tools to use. It is a 
constant battle to choose a tool that is responsive and relevant to clinical outcomes, and is 
concise and easy to administer6. The responsiveness of the instrument is an important 
consideration, because the instrument may fail to detect a change which can result in false-
negatives75. The reliability and validity of these measurement tools are assessed using 
psychometric properties100.  
Vandenbroeck et al. (2011) conducted a systematic review to identify glaucoma-specific and 
vision-related functional status, disease specific, treatment specific, and overall QoL tools, based 
on FDA guidelines63. Vision-specific tools are useful to clinicians and are specific to the disease 
progression and treatments94. The disease-specific tools do not capture the multi-dimensional 
concept that QoL entails58.  
Selecting an instrument to measure PROs depends on the objectives and population under 
investigation97. Based on the literature, time constraints, ease of use, professional judgement, 
relevance to the study population and study outcomes, the following four PROs were assessed in 
our research study: social support and community integration as measured by the Community 
Integration Questionnaire (CIQ); depressive symptoms as measured by the Patient Health 
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Questionanire-9 (PHQ-9), vision-related quality of life (VRQoL) as measured by the National 
Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25); and preference based HRQoL as 
measured by the Time Trade-Off (TTO) technique.  
2.7.1 Social Support and Community Integration 
More people are living with disabilities and therefore, there needs to be an emphasis on the 
inclusion of social well-being to assist patients in rehabilitative strategies. Among patients with 
visual impairment, functional activities and participation in household, social and occupational 
activities are important outcome measures101.  
Previous literature identified that an essential component of functional independence and 
accessibility is being able to drive, and vision-related diseases may prevent individuals from 
driving. It has been found that individuals with visual impairment have a decrease in functional 
independence, since they are prevented from performing activities such as driving102. Since 
glaucoma is a disease that causes visual impairment, it influences the patients’ driving abilities, 
and it has been shown that non-drivers have poorer community integration than drivers103. Thus, 
it is important to be aware of these patients’ social support and level of community integration, 
as this can provide support for better tailored interventions.  In many other chronic disease 
populations, such tailored interventions support improvements in QoL104.   
Among other chronic disease populations, social support and community integration has been 
shown to affect mortality and predict self-reported disease outcomes104. Although, there are 
many instruments available to assess functional abilities, not many assess community integration 
as a multidimensional concept.  The 32-item Craig Handicap Assessment and Reporting 
Technique (CHART) is the most commonly used measure of integration; however, the CIQ is 
more comprehensible, brief and easy to administer, with good measurement properties (refer to 
Section 4.5.1 for a detailed description of the CIQ)105.  
The CIQ was originally developed by an expert panel with experience in various aspects of 
rehabilitation and research for individuals with traumatic brain injury to assess changes in social 
functioning106,107. It focuses on behavioural states rather than emotional states. It consists of three 
domains that are consistent with the WHO definition of disability: home integration, social 
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integration and productive activity101. Some items measure the frequency of activities performed 
and other items measure the degree to which assistance is required to perform activities101. The 
International Classification of Functioning, Disability and Health (ICF) framework consists of a 
functioning and disability domain that includes activity and participation, which coincides with 
the CIQ items. The CIQ score ranges from 0 to 29 (greater social support and community 
integration). Previous studies among brain trauma patients reported that age, sex and level of 
education to have an effect on CIQ scores and females scored higher in the home integration 
domain whereas males scored higher in the productive activity domain108. Previous studies using 
the CIQ that were comparable to our study population, were conducted among geriatric patients 
and patients with physical disabilities101,109. 
Overall, the CIQ is interpretable and feasible in assessing the level of social support and 
community integration. With diseases that result in some form of disability, it is important to 
consider outcome measures related to social functioning to evaluate quality of care and need for 
care beyond medical treatment such as rehabilitation care coordination. Although, the CIQ has 
not been used in patients with ocular diseases such as glaucoma, vision loss is debilitating, thus it 
is important to consider the social integration of such individuals. Functional activity and 
participation are important outcomes across all diseases. The CIQ is generally applicable to 
patients with a disability and has been used in a heterogeneous sample of adult patients with 
disabilities101. 
2.7.2 Depressive Symptoms  
Vision loss can negatively influence the emotional well-being of individuals78.  More 
specifically, vision loss is associated with an increased risk of depression110. Among glaucoma 
patients, depression can arise due to fear of potential blindness, burden of treatments and 
impairments of activities of daily living16. There is the well-known social stigma around mental 
illnesses and ophthalmologists may not be aware of such conditions when treating their patients. 
There also exists a relationship between QoL and depression16. Tastan et al. (2010) found QoL to 
be negatively associated with depression in Turkish patients with glaucoma111. Depression can 
also results in disability and loss of productivity112. Thus, measuring depressive symptoms may 
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be relevant to the care of patients with glaucoma and other ocular diseases, to provide these 
patients with the necessary support and resources.  
Lim et al. (2016) reported mild to severe depressive symptoms among 30% of glaucoma patients 
in Singapore, using the Hamilton Depression Rating Scale (HAM-D)16.  Lim et al. (2016) also 
found variables such as sex, race, clinical characteristics and average NEI VFQ-25 scores were 
significantly associated with depressive symptoms16.  Further, Skalicky et al. (2008) determined 
that among their study population, depression prevalence increased with glaucoma severity, 
using the Geriatric Depression Scale-15113.  
The PHQ-9 was developed as a diagnostic tool for depression. It is one of the most common 
validated tools used to measure depression in research to identify depressive symptoms. It 
measures the severity of depression into five categories: none, mild, moderate, moderately severe 
and severe. It is a rapid assessment tool and it scores each of the nine “Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition” (DSM-IV) criteria. It is a brief standardized valid tool 
for assessing depressive symptoms. The PHQ-9 was found to support diagnosis made by 
clinicians and other screening instruments such as the Beck Depression and Anxiety Inventories 
and the Center for Epidemiologic Studies Depression Scale114. Previous research concluding the 
PHQ-9 as an adequate tool for diagnosing depressive disorders have been conducted in primary 
care settings114. 
To date, the PHQ-9 was not used in patients with ocular diseases such as glaucoma. Generally, 
as the PHQ-9 depression severity increased, there was a decrease in functional status, increase in 
health utilization and decrease in work productivity115. Typically, measures of depression have 
been assessed as part of a larger measurement tool consisting of a broad array of domains, such 
as the Short Form health survey. However, for our research study, the PHQ-9 was used to 
capture the specific dimension of emotional well-being.   
2.7.3 Vision-related Health-Related Quality of Life 
The most widely used instrument in vision-related functioning is the NEI VFQ-25. It was 
designed specifically for a clinical setting and consists of 12 domains: general health, general 
vision, visual pain, near activities, distance activities, social functioning, mental health, role 
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difficulties, dependency, driving, colour vision and peripheral vision76. It was developed to 
measure vision-specific functioning and impact of vision problems on HRQoL for various ocular 
conditions. Both the 51-item and the shorter 25-item version questionnaires were widely used in 
different groups of patients and shown to be internally consistent, reproducible and responsive in 
glaucoma patients9. Vision-specific instruments were found to be more sensitive and relevant to 
glaucoma than generic QoL instruments, as it contains items regarding activities of daily living, 
social functioning and coping related to vision loss57. The NEI VFQ-25 scores have a closer 
relationship to clinical outcomes, in comparison to generic instruments 95 .  
In the Early Manifest Glaucoma Trial, newly diagnosed glaucoma patients were randomized to 
receive treatment or no initial treatment. Patients scored a high mean composite score of 88.8 out 
of 100 on the NEI VFQ-25 scale116. Although early treatment significantly reduced clinical 
outcomes of glaucoma progression, it did not affect VRQoL scores116.  In addition, the NEI 
VFQ-25 scores were correlated with low visual acuity in the better-seeing eye, worse MD and 
lens opacities, but no correlation was found with age, sex, IOP, cardiovascular disease or 
systemic hypertension116. In the Los Angeles Latino Eye Study, a correlation was observed 
between visual field loss and NEI VFQ-25 subscale scores117. Findings from previous studies 
suggest that glaucoma patients with visual field loss report lower VRQoL scores9,76,117. In 
addition, previous studies found the composite NEI VFQ-25 scores of patients with glaucoma to 
be lower, and lower scores were correlated with more severe visual field defects118.  
As opposed to a generic or glaucoma-specific instrument, a vision-specific instrument was 
selected for our research study. Patients with glaucoma may present with other concurrent ocular 
conditions as well, thus our research study included patients diagnosed with various ocular 
conditions, including glaucoma and glaucoma suspects. A glaucoma-specific instrument would 
have been too limited and a generic instrument would have been too broad. Hence, a vision-
specific instrument was determined to be valid for our study population.  
2.7.4 Preference-Based Health-Related Quality of Life 
Although non-preference-based measures are useful in identifying declines in visual function, 
they do not assess how the patient’s visual function influences their daily life119. Thus, it is 
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necessary to assess the patients’ perception of their own health state.  Preference-based HRQoL 
outcomes use utility values to present the preference values of the patient.  
 
The two most common methods of assessing utility values are the TTO and standard gamble 
(SG) methods. The TTO technique s a tool used in health economics to help determine HRQoL 
of patients, where the patient trades the length of life for QoL. In ophthalmology, the utility 
value is calculated by dividing the number of years a patient is willing to trade for perfect vision 
by the numbers of years expected to live, subtracted by 1.0120. Utility values are rated on scale 
between death (utility = 0.0) and perfect health (utility = 1.0). On the other hand, with the SG 
method, the patient is presented with a theoretical treatment and two possible outcomes 
(treatment works or does not work)120. Patients are then asked the percent chance of blindness 
they are willing to risk before refusing the treatment120. The percentage obtained is then 
subtracted from 1.0 to obtain the SG utility value, which describes how undesirable the patient 
perceives their present health state (i.e., the more risk the patient is willing to tolerate, the less 
desirable they perceive their health state)120.  The TTO technique is easier to administer than the 
SG method119.  
Utility values were previously used to measure preference-based HRQoL among glaucoma 
patients. Total visual acuity, visual acuity in the better eye and comorbidity significantly affect 
utility scores9. A study of glaucoma and glaucoma suspect patients, reported on average high 
TTO utility values of 0.93 and 0.98 respectively (22% glaucoma and 11% glaucoma suspect 
patients were willing to trade some years of their remaining life expectancy for perfect 
vision)119,121. On the other hand, a study of Indian glaucoma patients reported on average a low 
TTO utility value of 0.64, representing a poorer preference-based HRQoL96. Gupta et al., (2005) 
found significant associations between TTO utility values and the degree of visual acuity loss 
and educational status96. The utility values were found to be poorly correlated with visual field. 
Patients who were blind reported a lower average utility value of 0.67, meaning that they were 
willing to trade more years for perfect vision. Bass et al. (1997) assessed the utility value of 
patients prior to cataract surgery, and found that TTO utility values were closely related to 
feelings of depression and difficulties with social interactions more so than clinical meausres122. 
Brown et al. (1999) found that visual loss is associated with a decrease in the patients’ 
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preference-based HRQoL, in which patients with a poor visual acuity value (i.e., counting 
fingers) were willing to give up more years of their remaining life compared to patients with a 
better visual acuity (i.e., 20/20)123. A study of Chinese patients reported a mean utility value of 
0.88, suggesting that most were not willing to trade their remaining years for perfect vision124. 
Aspinall et al. (2008) reported that only 17% of the patients were willing to consider trading their 
remaining years of life for perfect vision125.  
The TTO technique is a preference-based measure that assesses the subjective impact of diseases 
on HRQoL and provides information for economic evaluation. It overcomes the limitation of 
many questionnaires that provide a composite measure, by using preference-based choices to 
provide a numerical value representing the patients HRQoL120. Although utility measures lack 
precision, unlike other HRQoL measures, they allow for comparison across various disease 
states119. Hence, the TTO technique was used for our research study. 
2.8 Linking Clinical Variables with Patient-Reported Outcomes 
Health outcomes are influenced by clinical factors, characteristics of the individual and 
environmental factors (i.e., healthcare facility, social support system). Several different PRO 
measures are used, which makes it difficult to compare results across studies126. In addition to 
literature review and expert opinions, the Wilson and Cleary (1995) model was adapted to 
identify variables and outcome measures for our research study.  
The Wilson and Cleary (1995) model incorporates biological, social and psychological domains 
to present the relationships among measures of patient outcomes (Figure 2-1)19. The model 
illustrates that all components lead to an overall HRQoL as the endpoint. However, the purpose 
of our research study was not to assess overall HRQoL, but rather specific domains of HRQoL. 
Thus, the model was adapted to fit our research objectives (Figure 2-2). The characteristics of the 
environment were excluded, since all patients were recruited from the same health care 
institution and were cared for by the same ophthalmologist.  Although the original model 
developed by Wilson and Cleary (1995) illustrates causal relationships between adjacent 
domains, we adapted the model so that relationships could exists between nonadjacent 
domains19,127. The premise was that understanding these relationships are important for glaucoma 
treatment and management.  
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Figure 2-1. Health-related quality of life conceptual model. Developed by Wilson and 
Cleary, JAMA 1995; 273(1): 59-65 
 
Figure 2-2. Adapted Wilson and Clearly (1995) model for glaucoma and glaucoma suspect 
patients 
2.9 Predicting Patient-Reported Outcomes  
The term prediction is used in machine learning to estimate the outcome for the value of a new 
unobserved variable128. In machine learning, no distinction is made between variables that could 
in principle be observed immediately (e.g. predict a patient’s age, given their occupation) and 
those that are not observable until some future point in time (e.g. predict whether the patient will 
develop glaucoma over the next five years). Thus, the term prediction is relative to the state of 
knowledge of the model making the prediction, not relative to the “true” observed value of the 
variable. In machine learning, the variables in the model (i.e., input or independent variables) are 
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often called predictor variables128. For the context of this thesis, independent variables are 
referred to as predictor variables.  
Predictive models may help ophthalmologists improve glaucoma management by assessing the 
patient’s perceived health status and values. Such an approach is of high interest to governments 
which are interested in providing cost-effective, and yet, quality care. Compared to administering 
several different PRO instruments, a predictive tool can be an efficient method to assess patient 
needs for health care decisions. Studies aiming to predict outcomes or identify factors associated 
with an outcome need to go beyond simple regression models and significance of covariates to 
make conclusions. A literature review conducted in 2015 identified machine learning approaches 
used in clinical vision sciences for image processing and glaucoma diagnosis23. Most of the 
machine learning techniques in glaucoma research were used to improve the diagnosis of 
glaucoma23.  
Identifying predictor variables for HRQoL have been done in studies among conditions such as 
obesity, schizophrenia, multiple sclerosis, back pain, other chronic conditions and patients after 
undergoing surgical procedures127,129–135. However, the methodology used in identifying 
predictor variables is not consistent across studies. Benedict et al. (2005) and Kowalchuk et al. 
(2009) performed multivariable linear and/or logistic regression methods to identify the best 
subset of predictors of HRQoL and patient outcomes130. Bow-Thomas et al. (1999), Horng et al. 
(2005) and Khedmat et al. (2007) used stepwise regression to identify significant variables to be 
included in their predictive models129,132,134. Khedmat et al. (2007) further assessed the model 
accuracy of the derived model134. Hatzmann et al. (2009) and Heslin et al. (2011) used structural 
equation modeling to determine a final model to predict HRQoL133,136. Wang et al. (2013) 
identified factors associated with HRQoL among overweight/obese adults by using multivariable 
modeling and selected the best model based on Mallow’s complexity parameter (Cp), R-squared, 
adjusted R-squared statistics135. 
There were a few studies that used machine learning techniques to predict PROs among patients 
with ocular conditions95,137. Browne et al. (2012) assessed model performance and model fit to 
estimate a model that predicts PROs (four generic HRQoL instruments and the NEI VFQ-25) 
based on vision-specific measures95. The model performance was assessed using mean absolute 
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error (MAE), mean square error (MSE) and root mean square error (RMSE), and model fit was 
assessed using R-squared 95. The ordinary least squares model was chosen as the best-performing 
model, based on the lowest RMSE and MAE and highest R-squared 95. The only clinical 
variables included in the model were visual acuity, contrast sensitivity and visual field95. 
Hirasawa et al. (2014) used the Sumi Visual Disability Questionnaire to predict VRQoL using 
only visual field and visual acuity, and the prediction error was calculated using RMSE with 
leave-one-out cross validation137. They found a smaller RMSE with the machine learning model 
compared to the linear and stepwise regression model137.   
Our research study is interested in performing machine learning techniques to identify variables 
that are most predictive of PROs. Not only were important clinical variables used, but important 
characteristics of patients that were not collected typically during a comprehensive eye exam 
were used as well.  
2.10 Summary of the Gaps in the Literature  
There is a growing recognition that it is important to assess patients’ health outcomes in a 
multidimensional approach to include PROs, because there are many factors that influence 
health. Despite the benefits, it may be burdensome for ophthalmologists and patients to routinely 
assess PROs in clinical practice and there are no clinical guidelines specifying the use of PROs. 
Although, research studies have incorporated PROs, there is no specification as to which PRO is 
best to be used in ophthalmic practice. At a time when health policy makers are asking for 
metrics of quality of care, it is incumbent upon health care providers to develop and implement 
systems that efficiently address this need. 
The importance of increasing patient input into health care decision making has become a very 
contemporary topic in many countries, including Canada. However, it has also been recognized 
that, this needs to be done in the most efficient way possible in order to be implemented and 
sustainable. Thus, our research study aims to identify predictor variables that are most strongly 
associated with PROs through rigorous methodologies that previous studies among glaucoma 
patients have not addressed.  
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Chapter 3  
3 Thesis Rationale and Thesis Objectives  
3.1 Thesis Rationale 
There is an increased need to incorporate PROs in clinical care. In addition to the clinicians’ 
assessment of the patient, PROs are necessary for tailored optimal care, because although 
patients have good clinical outcomes, their perceptions of their health state may be poor and vice 
versa.  Obtaining data on PROs is also useful for policy makers to incorporate direct patient 
input into health care decision making policies. However, incorporating PROs to daily clinical 
practice can be challenge. A stream-lined process that would provide the highest yield of 
relevant data would allow for broad uptake in the clinical setting. Thus, my thesis aimed to 
answer the following question: What clinical and/or demographic variables are most predictive 
of important PROs? Pertaining to my project and patient population, important PROs are defined 
as social support and community integration, depressive symptoms, vision-related quality of life 
(VRQoL) and preference based health-related quality of life (HRQoL).  
3.2 Thesis Objectives  
1. To assess social support and community integration as measured by the Community 
Integration Questionnaire (CIQ), and determine which clinical and/or demographic 
variables are associated with the overall score, in glaucoma suspects and patients 
diagnosed with glaucoma. 
2. To assess depressive symptoms as measured by the Patient Health Questionanire-9 
(PHQ-9), and determine which clinical and/or demographic variables are associated with 
the presence or absence of depressive symptoms, in glaucoma suspects and patients 
diagnosed with glaucoma. 
3. To assess VRQoL as measured by the National Eye Institute Visual Function 
Questionnaire-25 (NEI VFQ-25), and determine which clinical and/or demographic 
variables are associated with the composite score, in glaucoma suspects and patients 
diagnosed with glaucoma. 
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4. To assess the preference-based HRQoL as measured by the Time Trade-Off (TTO) 
technique and determine which clinical and/or demographic variables are associated with 
the utility values, in glaucoma suspects and patients diagnosed with glaucoma.  
5. To develop models for predicting social support and community integration, presence of 
depressive symptoms, VRQoL and preference-based HRQoL based on clinical and/or 
demographic variables, and validate the resulting models 	
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Chapter 4  
4 Methods 
This chapter begins with an overview of the study design and sampling procedures (Section 4.1), 
sample size calculation (Section 4.2), and data collection methods (Section 4.3). Following is an 
overview of the predictor variables measured (Section 4.4) and outcome measures used (Section 
4.5). This chapter concludes with a detailed description of the statistical analysis procedures 
(Section 4.6).  
4.1 Study Design and Sampling Procedures 
This study was a cross-sectional design.  Two hundred and fifty patients who were identified as 
glaucoma suspects (refer to Section 4.4.2.5 for definition of glaucoma suspects) or had been 
diagnosed with glaucoma were recruited from a single ophthalmic practice with an 
ophthalmologist specializing in glaucoma, at the Ivey Eye Institute, St. Josephs Health Care 
London, Ontario. Patients were sequentially recruited from February to August 2016 using 
convenience sampling. As patients came in for their regular ophthalmology visits, their eligibility 
was determined by the ophthalmologist. Inclusion criteria included patients who were diagnosed 
with glaucoma or who were glaucoma suspects and their willingness and ability to answer the 
questions in the measurement tool. Exclusion criteria included patients who were unable to 
participate due to language restrictions. All participants received a complete explanation of the 
purpose and procedures involved in the study and patient concerns were addressed prior to study 
participation. Both verbal and written informed consent was obtained from all participating 
patients. The study was initiated after approval by Western University’s Research Ethics Board 
(refer to Appendix A for the approval letter) and Lawson Health Research Institute’s Clinical 
Research Impact Committee. 
4.2 Sample Size Calculation 
Since the Community Integration Questionnaire (CIQ) and Patient Health Questionnaire-9 
(PHQ-9) measures were not previously assessed in our study population, the effect size for the 
sample size calculation was determined based on the Time Trade-Off (TTO) technique. The 
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effect size for the TTO utility score was determined based on the study conducted by Sharma et 
al. (2000)138. The power approach was used which involved specifying a hypothesis test, 
significance level (a), effect size and value of the power. For purposes of the sample size 
calculation, the null hypothesis is defined as the model with just the intercept (i.e., when all 
predictor variables = 0). The null hypothesis is testing whether the null model (i.e., model with 
only the intercept) is better than the alternative model with the predictor variables added. We 
determined the required Cohen’s f2 effect size for an F-test to be 0.2 and specified that such an 
effect be detected with 80% power, when the significance level is a=0.05 with 27 predictor 
variables (this includes the levels within a categorical variable). An online sample size calculator 
was used to calculate an a-priori sample size for multiple regression139.  To compute the sample 
size, the online calculator used nine formulas that is provided in Appendix B139. 
 
The minimum required sample size calculated was n=139. Accounting for subject recruitment, 
we determined a study sample size of n=250 to be sufficient. In comparison, sample sizes of 
previous observational studies ranged from 73 to 32587,95,96,119,124,125,138,140–153. 
4.3 Data Collection Methods 
Clinical and demographic variables were collected by two methods: face-to-face interviews and 
retrospective medical chart review. All data were recorded on paper data collection forms and 
then single data entry was performed into a password protected Microsoft Excel spreadsheet.  
Data quality checks were performed at random.  
4.3.1 Face-to-face Interview 
After the clinical examination, questionnaires were delivered in person. The actual 
administration of the questionnaires was a combination of interviewer administered and self-
administration modes. Patients were interviewed under standardized conditions to determine five 
demographic variables and utility values by the Time Trade-Off (TTO) technique. The 
interviews were conducted by a single interviewer. All other questionnaires – Community 
Integration Questionnaire (CIQ) and Patient Health Questionnaire (PHQ-9) and the National Eye 
Institute Visual Function Questionnaire-25 (NEI VFQ-25) were completed by the patient in 
  
 
 
33 
paper format. The researcher was present while the patient was completing the questionnaires 
and was available to address any patient concerns and administer the questionnaire if patients 
had difficulties completing the questionnaires on their own.        
4.3.2 Retrospective Chart Review 
Clinical variables were obtained mainly through medical chart review or in combination with 
face-to-face interviews. A total of thirteen predictor variables were measured. 
4.4 Predictor Variables  
The Wilson-Cleary conceptual model19 was adapted (Figure 2-2), review of the literature and 
expert opinions were used to refine and select variables to measure. Predictor variables were 
categorized to ensure adequate representation in each category.  
4.4.1 Demographic Characteristics 
Demographic characteristics collected include: age, sex, income, education, living arrangement 
and use of mobility aids. Typically, age and sex are variables that are collected and recorded in 
the patient’s medical charts. However, income, education, living arrangement and use of 
mobility aids are variables that are not collected during a typical comprehensive eye exam.  
4.4.1.1 Age 
The Century Month Code (CMC) is a form of reporting dates that is used in major surveys such 
as the Demographic and Health Survey (DHS), to simplify working with data coded by month 
and year154. It represents dates using a reference date of January 1st 1900. CMC is calculated by 
multiplying the difference between the year of interest and 1900, by 12 and then adding the 
month: 
CMC (month, year) = 12 (year – 1900) + month 
A continuous measure of age in years was calculated by computing the difference between the 
CMC of the date of visit and the date of birth.  
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4.4.1.2 Sex 
Sex is a binary variable that was coded as Female = 1 (the reference category) and Male = 2. 
4.4.1.3 Income 
Current yearly income status of the patient was collected during the face-to-face interview. 
Patients were asked to choose their income range from the following eight categories: less than 
$10 000, $10 001 to 25 000, $25 001–$50 000, $50 001–$75 000, $75 001–$100 000, $100 001–
$125 000, $125 001–$150 000 and greater than $150 000. To collect accurate income data these 
8 categories were used. Prior to analysis, to obtain a better distribution of the data and exclude 
categories that do not contain any responses, the eight income categories were grouped into three 
categories: less than $25 000 (code = 1; the reference category), $25 000–$50 000 (code = 2) and 
greater than $50 000 (code = 3). 
4.4.1.4 Education 
Patients were asked to select their highest level of education completed from the following seven 
categories: some high school or less, completed high school, additional training (apprenticeship, 
trade or vocational school, etc.), college degree, undergraduate university, postgraduate 
university and advanced professional degree. For better data distribution, the response categories 
were collapsed to provide a binary variable: completed high school or less (code = 0; the 
reference category) and completed more than high school (code = 1).  
4.4.1.5 Living Arrangement 
Patients were asked to select their living arrangements given the following seven categories: 
home alone, home with spouse, home with family, home with caregiver, nursing home, long-
term care home and retirement home. To exclude categories with no responses and for a better 
distribution of the data, the seven response categories were collapsed into three categories: home 
alone (code = 1; the reference category), home with family/spouse/caregiver (code = 2) and 
nursing/retirement home (code = 3). 
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4.4.1.6 Use of Mobility Aids 
Patients were asked if they used mobility aids, and if they responded yes, then they were asked to 
specify the type of mobility aids used: a cane, walker, wheelchair or motorized scooter. This 
variable was dichotomized as: does not use mobility aid (code = 1; the reference category) and 
does uses mobility aid (code = 2).   
4.4.2 Clinical Characteristics 
The clinical characteristics collected include: best corrected visual acuity, number of 
comorbidities, number of ocular conditions, number of ocular procedures, glaucoma stage, time 
since diagnosis, initial treatment. These clinical characteristics are typically collected during a 
comprehensive eye exam.  
4.4.2.1 Best Corrected Visual Acuity  
Vision function is measured quantitatively through visual acuity and visual field assessments. 
Visual acuity measures the ability of the eye to identify shapes and details of objects at a given 
distance and to detect any changes in vision70. Best corrected visual acuity (BCVA) refers to the 
measurement ‘with correction’, such as with glasses or contact lens. Snellen acuity chart was 
used to test visual acuity for the study patients, in addition to Count Fingers (CF), Hand Motion 
(HM), Light Perception (LP) or No Light perception (NLP) for those patients whose vision was 
worse than 20/400.  
The International Classification of Diseases (ICD-9) categorizes vision as: mild vision 
impairment (code = 1; the reference category), moderate vision impairment (code = 2) and legal 
blindness (code = 3). Mild vision impairment is defined as BCVA between 20/32 and 20/63; 
moderate vision impairment is defined as BCVA between 20/80 and 20/160; legal blindness is 
defined as BCVA is 20/200 or worse71. With regards to eye diseases that affect peripheral vision, 
as in glaucoma, it appears that the worse-seeing eye has a stronger influence on VRQoL118. Thus, 
the BCVA in the worse-seeing eye was obtained from the medical charts.  
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4.4.2.2 Number of comorbidities 
First, patients were asked if they had any other comorbidities, and if yes, they were asked to 
specify the type of comorbidity by selecting from the following categories: cardiovascular, 
neurological, respiratory, immunocompromised, cancer, infectious disease, musculoskeletal, 
gastrointestinal, endocrine/metabolic, psychological and other.  
 
Secondly, the researchers verified and validated the listed comorbidities by reviewing patients’ 
medical charts. For analysis, the number of comorbidities was identified and treated as a 
continuous variable.   
4.4.2.3 Number of Ocular Conditions 
Patients were asked if they had any other ocular diseases besides glaucoma. All conditions such 
as cataracts, pseudoexfoliation syndrome, age-related macular degeneration were recorded. 
Patients’ responses were verified through medical chart reviews. This variable was treated as a 
continuous variable. 
4.4.2.4 Number of Ocular Procedures 
Patients were asked if they had any ocular procedures performed, such as cataract surgery. 
Patients’ response were verified through medical chart reviews. Number of ocular procedures 
was treated as a continuous variable. 
4.4.2.5 Glaucoma Stage 
The Canadian Ophthalmological Society defines four stages of glaucoma based on clinical 
characteristics22: 
Suspect Glaucoma (code = 1; the reference category): suspicious cup-to-disc (C/D) 
asymmetry of >0.2. 
Early Glaucoma (code = 2): Vertical C/D ratio of <0.65, and/or mild visual field defect not 
within 10 degrees of fixation, mean deviation(MD) better than -6dB. 
Moderate Glaucoma (code = 3): Vertical C/D ratio between 0.7 and 0.85, and/or moderate 
visual field defect not within 10 degrees of fixation, MD from -6dB to -12dB. 
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Severe Glaucoma (code = 4): Vertical C/D ratio of >0.9, and/or visual field defect within 10 
degrees of fixation, MD worse than -12dB. 
Glaucoma stage was determined from the most recent clinical characteristics found in the 
patient’s medical chart, and was treated as a categorical variable with four levels.  
4.4.2.6 Time Since Diagnosis 
Time since glaucoma or glaucoma suspect diagnosis was obtained from the patient’s medical 
chart. The difference between the date of study visit and date of diagnosis was computed as a 
continuous measure. To improve the precision of this measure, the unit of measure was 
converted from years to months.   
4.4.2.7 Initial Treatment 
The treatment options for the study patients were obtained from medical charts, which included: 
medication (code = 0, the reference category), selective laser trabeculoplasty (SLT) (code = 1) or 
observation (code = 2). This variable was treated as a categorical variable with three levels.  
4.5 Patient-Reported Outcome Measures 
Four separate measurement tools were used to determine each of the four outcomes: patient’s 
level of social support and community integration, presence of depressive symptoms, vision-
related quality of life (VRQoL) and preference based HRQoL.  
4.5.1 Community Integration Questionnaire  
The CIQ was used to provide a quantitative indicator for the level of social support and ability to 
perform appropriate roles at home and within the community108. The CIQ contains 15-items and 
uses behavioural items of integration to achieve better reliability60. The CIQ used for this study is 
presented in Appendix B.  
The CIQ was administered during the face-to-face interview process and took the patients about 
5 to 10 minutes to complete. The CIQ was completed by the patient, with an interviewer present 
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for assistance. The original scoring procedures were followed for this study, which produced a 
total score and three subscale scores107,108: 
Home Integration: 0 to 10 points; consists of 5 items assessing activities that were 
typically done independently such as housework, child care, household shopping, meal 
preparation and planning social arrangements. The response options included: yourself 
alone, yourself and someone else or someone else.  
Social Integration: 0 to 12 points; consists of 6 items assessing frequency of activities 
that relate to leisure activities, shopping, personal finance management, visiting family 
and friends, having a best friend and engaging in leisure activities. The response options 
included the frequency of participating in such activities and with whom these activities 
are done with.  
Productive Activities: 0 to 7 points; consists of 4 items assessing frequency of activities 
that relate to volunteer activities, travel, student and employment status.  
The total CIQ score ranges from 0 to 29, with a higher score representing a higher level of social 
support and complete community integration108. The CIQ was adapted for use in our research 
study. One of the options for item 10, ‘Mostly with friends who have head injuries’ was changed 
to ‘Mostly with friends’ to be applicable to our patient population. All other items remained the 
same. The total CIQ score was analyzed as a continuous outcome using linear regression. 
Prior studies mainly assessed psychometric characteristics of the CIQ in a sample of traumatic 
brain injury patients, thus little is known about the psychometric properties among other patient 
groups101. However, a cross-sectional study published in 2010, tested the CIQ across various 
debilitating diseases, aging and traumatic conditions74. In addition, a recent study assessed the 
CIQ in a geriatric population109. Seale et al. (2002) reported relative reliability coefficients for 
home integration (r=0.71), social integration (r=0.70), productive activities (r=0.63) and CIQ 
total (r=0.81). In 2000, Cusick et al. reported intraclass correlation coefficients (ICC) as a 
measure of the test-retest reliability of the CIQ: 0.88 for home integration, 0.66 for social 
integration, 0.80 for productive activities and 0.86 for CIQ total155. Most recently, Singh & 
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Sharma (2015), reported excellent ICC among a geriatric population (ICC=0.99)109. Overall, 
studies have reported adequate to excellent test-retest reliability across the three domains. 
Studies assessing the psychometric properties of the CIQ have reported evidence for discriminant 
validity comparing disabled to nondisabled individuals, differentiating scores among individuals 
living independently and with support and moderate to strong interrater reliability101,106,108. Past 
studies have reported the total CIQ score to be adequate in assessing community integration105. 
Reliability of the CIQ is generally acceptable and the validity was evaluated by difference in 
CIQ scores by sex, age and wheelchair use106.  
4.5.2 Patient Health Questionnaire - 9 
The PHQ-9 was used to measure the presence of depressive symptoms. The PHQ-9 contains 9-
items that represent DSM-IV specific diagnosis of depressive disorder115. The PHQ-9 used in our 
study is presented in Appendix C. 
The PHQ-9 was completed by the patient, with an interviewer present for assistance. It took the 
patient about 5 minutes to complete the questionnaire. The PHQ-9 provides a total score that 
translates into the following four categories: minimal, mild, moderately severe and major 
depressive symptoms. Patients rate the difficulty of performing tasks such as: work, home 
activities and associations with others. Patients were asked how much each symptom has 
bothered them over the past two weeks, with respect to the following response options and 
scores: “not at all” (score = 0), “several days” (score = 1), “more than half the days” (score = 2) 
and “nearly every day” (score = 3). A final item assessed the degree to which the depressive 
symptoms influenced social, functional and occupational impairment156. The total PHQ-9 score 
was scored on a scale from 0 to 27, with the higher score representing more severe depressive 
symptoms. The scores assigned to the PHQ-9 categories are as follows: minimal symptoms (5 to 
9), mild symptoms (10 to 14), moderately severe symptoms (15 to 19) and major depressive 
symptoms (> 20). The scoring scale used for PHQ-9 does not account for scores less than five. 
For our research study, to capture the PHQ-9 total scores of less than five, the score was 
dichotomized to the presence or absence of depressive symptoms. Thus, the score was 
categorized as ‘no depressive symptoms’ (code = 0; the reference category) and ‘some 
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depressive symptoms’ (code = 1). ‘No depressive symptoms’ consisted of a PHQ-9 score 
ranging between zero and four and ‘some depressive symptoms’ consisted of a PHQ-9 score 
greater than four. The PHQ-9 score was analyzed as a binary outcome using logistic regression.  
 
The PHQ-9 has strong internal and test-retest reliability as well as construct and factor-structure 
validity156. PHQ-9 demonstrated good internal reliability, with Cronbach’s coefficient alpha 
values of 0.842, 0.846, 0.816 across three different trials112. Limited studies investigated the 
validity of PHQ-9. The sensitivity of the PHQ-9 detecting depressive disorders was fair 
(sensitivity=0.64)114. Kroenke et al. (2001) assessed the construct validity of the PHQ-9 using 
the Short Form General Health Survey and reported 88% sensitivity and specificity for a PHQ-9 
score ³10115. 
4.5.3 National Eye Institute Visual Function Questionnaire - 25 
The NEI VFQ-25 was used to determine the vision-related quality of life (VRQoL) of the 
patients. It contains 25 items, 24 of which are vision-related. The NEI VFQ-25 used in our study 
is presented in Appendix D. The items were divided into three parts: general health and vision, 
difficulty with activities and responses to vision problems. The items were scored according to 
12 domains: general health (1 item), general vision (1 item), ocular pain (2 items), near vision (3 
items), distance vision (3 items), social functioning (2 items), mental health (4 items), role 
functioning (2 items), dependency (3 items), driving (3 items), colour vision (1 item) and 
peripheral vision (1 item)157. The driving score was only documented for patients who were 
drivers. Mean composite and subscale scores can be obtained from this questionnaire. Most 
items were recorded on a scale of 1 to 5 or 1 to 6, each item was then converted to a 0 (worst 
possible score) to 100 (best possible score) scale18. For purposes of this study, only the NEI 
VFQ-25 composite score was used to capture an overall measure of VRQoL. The NEI VFQ-25 
composite score was an average of the 11 vision-related domains, with the exclusion of general 
health. The general health item was treated as a stand-alone item157. The composite score ranged 
from 0 to 100, with a higher score representing better visual functioning. By taking the average 
of each domain, as opposed to average of each item, equal weight was given to each domain157. 
NEI VFQ-25 was completed by the patient, with an interviewer present for assistance. Patients 
were asked to respond to all items as though they wore glasses or contact lenses to correct their 
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vision. It took the patient about 10 minutes to complete the questionnaire. The NEI VFQ-25 
score was analyzed as a continuous outcome using linear regression.  
 
Internal consistency estimates of each domain ranged from 0.71 to 0.85, representing an 
acceptable reliability157. Berdeaux et al. (2005) and Revicki et al. (2010), reported Cronbach’s 
alpha coefficients for the NEI VFQ-25 composite score of 0.94 and 0.96, respectively118. 
Mangione et al. (1998) defined the psychometric properties of the NEI VFQ-25 and suggested 
that the 12 domains represent a broad dimension of VRQoL100. Mangione et al. (2001) tested the 
psychometric properties of the NEI VFQ-25 and reported evidence of between group validity157. 
The reliability and validity of NEI VFQ-25 was reported to be similar as the NEI VFQ-51119. On 
average the NEI VFQ-25 score predicts about 92% of the variance in the NEI VFQ-51 score157. 
Thus, previous studies demonstrated good reliability and validity of the NEI VFQ-25 in terms of 
measuring vision-related outcomes across various ocular diseases158.   
4.5.4 Time Trade-Off Technique 
The TTO technique was used to obtain utility values. Patients were asked a 2-part question: 
1. “How many years do you expect to live?” 
2. “Suppose that there was a new technology that could restore your eyesight to perfectly 
normal in both eyes. The technology always works but decreases the length of time you 
live. What is the maximum number of years, if any, that you would be willing to give up if 
you could receive this technology and have perfect vision for your remaining years?” 
 
The TTO utility values were calculated by dividing the number of years the patient is willing to 
give up for perfect vision by the number of years expected to live, and subtracting the obtained 
proportion from 1.0148. The utility value ranges between 0 (death) to 1 (perfect visual health). For 
example, consider a patient who expects to live for another 20 years and is willing to give up 5 
years for perfect vision. The patient’s utility value would be generated by subtracting the 
proportion of remaining years traded for perfect vision (0.25 or 25%) from the state of perfect 
visual health (1.0 or 100%). The resulting utility value of 0.75 (75%), represents the patient’s 
perception of their HRQoL. The larger the proportion of remaining years that a patient is willing 
to trade for perfect vision, the lower the associated utility value. Generally, the TTO utility 
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values are analyzed using linear regression. However, given the data obtained for our study 
population, linear regression would not be the best fit, since it would result in a zero-inflated 
model. Therefore, for this study the utility values were categorized as those ‘not willing to give 
up any years of life’ (code = 0; the reference category) and those ‘willing to give up some years 
of life’ (code = 1). The format of the TTO technique used in our study is presented in Appendix 
E. The TTO technique was completed by the patient, with an interviewer present for assistance. 
The TTO utility score was analyzed as a binary outcome using logistic regression. 
 
Previous studies have demonstrated the validity of the TTO technique with respect to best 
corrected visual acuity (BCVA) in the better-seeing eye146. TTO technique has shown good 
reproducibility159. Hollands et al. (2001) showed good reliability (ICC=0.76) of the TTO 
technique among patients with ocular disease160. 
4.6 Statistical Analysis 
4.6.1 Univariate Analysis 
Predictor variables were explored one by one, using univariate analysis. Descriptive statistics 
were computed for all predictor variables and outcome variables. In order to understand the 
distribution of each predictor variable, frequencies were calculated for categorical variables (sex, 
income, education, living arrangement, use of mobility aid, BCVA, glaucoma stage, initial 
treatment, PHQ-9 and TTO). In order to understand the central tendency and distribution of 
continuous predictor variables, means and standard deviations were calculated for continuous 
variables (age, number of comorbidities, ocular condition, ocular procedures, time since 
diagnosis, CIQ and NEI VFQ-25).  
4.6.2 Missing Data 
Missing data are classified in terms of their probability as they relate to the predictor variable 
(observed data) and outcome variables (unobserved data). Missing at random (MAR) is when the 
probability of missing data may depend on the predictor variables, but not on the outcome161. 
Missing completely at random (MCAR) is when the probability of missing data are not related to 
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the predictor variable and outcome variables161. Missing not at random (MNAR) is when the 
probability of missing data is related to the outcome variable161. MCAR and MAR can be 
imputed without introducing systematic bias162.  
Missing data can occur for many reasons. In our research study, it was due to patients’ refusal to 
provide their income range and respond to the TTO technique. We believe the missing data were 
MAR conditioned on the other variables (i.e., education). The nonresponse rate was 7.2% (n=18) 
and 1.2% (n=3) for income and the TTO value, respectively. Considering that TTO value was an 
outcome of interest and the nonresponse rate was small, these individuals (n=3) were excluded 
from all analyses, reducing the sample size of 250 to 247.   
Imputation is the method used to fill in missing data. The advantage of using imputation is to 
provide a complete data set for analyses, increase efficiency and reduce bias. Single imputation 
is a process that analyzes the observed responses for the missing variable and provides one 
plausible response for the missing data point. The advantage of single imputation is that once the 
values are filled in, performing the necessary complete-data analyses are straightforward163. The 
disadvantage of single imputation is that it underestimates the uncertainty and variance. To 
overcome this disadvantage, multiple imputation provides a set of plausible responses and 
considers the uncertainty both within and between imputations161. In multiple imputation, the 
missing values are replaced by two or more stimulated values to create imputed datasets163. 
Statistical analyses are then conducted using each of the imputed datasets to calculate a point 
estimate that is adjusted for the missing data uncertainty163. The objective of multiple imputation 
is to provide valid statistical inferences163. 
To handle the missing data for income in our dataset, an ordinal variable, multiple imputation 
was performed, using the ordered logistic regression imputation method in STATA 13. Literature 
suggest that values imputed between 2 and 10 are sufficient to obtain valid inferences and since 
the percentage of missing values is low for income, thus we imputed 10 times163. We then 
analyzed the multiple imputed data with multivariable linear and logistic regression. This method 
of multiple imputation was used to estimate regression coefficients, but not for stepwise 
regression and Classification and Regression Tree (CART) analyses. 
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It is more difficult to handle missing data in prediction modelling, because for nonlinear models 
like CART there are no standard rules for combining models from different imputations. This is 
in contrast to Rubin’s Rules, which was used for the inference analyses163. Rubin’s Rules are 
based on the approach of combining the models obtained from multiple imputation to produce 
overall estimates, confidence intervals and p-values. Since our predictive modelling is not 
intended for inference, it is less crucial to consider the uncertainty (e.g., standard errors of 
estimates), whereas for inference modelling uncertainty was important to consider. Furthermore, 
in our research study less than 10% of all measured variables were missing (entirely from the 
income variable). Thus, for prediction analyses, we performed single regression imputation using 
the mode, in which the mode of the 10 imputations was treated as the actual income value and 
manually replaced to create a complete data set. This approach increases variance, in comparison 
to the traditional mean substitution method. This completed data set was used to perform 
stepwise regression and CART analysis. 
4.6.3 Bivariate Analysis 
Bivariate analysis was performed to assess the unadjusted effect estimates and check whether 
each predictor variable and outcome were associated. Each of the 13 predictor variables were 
individually investigated for association with all four outcomes, using simple linear and logistic 
regression analyses.  
4.6.4 Associations Between Predictor Variables  
Investigating the association between the predictor variables can provide information regarding 
difficulties when assessing the effects (i.e., if two predictor variables present high correlation, 
then the effect of one, when adjusted for the other predictor variables, cannot be estimated with 
high precision)164. Comparisons can be made between categorical and categorical, or continuous 
and continuous, or categorical and continuous variables. 
Pearson correlations were used to assess the association between pairs of continuous predictor 
variables. Correlation varies between -1 (perfect negative linear correlation) and +1 (perfect 
positive linear correlation), and 0 represents no correlation. The Pearson correlation coefficient 
threshold absolute value of 0.6 was used as a cut-off indicating a strong association between the 
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variables165. If a threshold above 0.6 was identified, then a significance test was conducted to 
confirm the association.   
Chi-square tests were used to assess the association between pairs of categorical predictor 
variables. Chi-square test is based on the difference between the expected and observed 
frequencies. Probability ranges from 0 (categorical predictor variables are independent) to 1 
(categorical predictor variables are dependent). The significance of the relationship between the 
predictor variables was defined at a<0.05. 
T-tests and one-way ANOVA were used to assess the associations between pairs of continuous 
and categorical predictor variables. T-test assess whether the means of two groups are 
statistically different from each other. ANOVA assess whether the means of three or more 
groups are statistically different from each other. Statistical significance was determined at 
a<0.05. T-test was used for the categorical variables with two levels: sex, education and use of 
mobility aid. One-way ANOVA was used for the categorical variables with more than 2 levels: 
income, living arrangement, BCVA, glaucoma stage and initial treatment.  
4.6.5 Regression Diagnostics 
The following assumptions were considered to examine the distribution of the predictor 
variables: linearity, normality, homoscedasticity, multicollinearity, model specification, 
independence. The linearity assumption considers that the relationship between the predictor 
variables and the outcomes should be linear. Component-plus-residual plot was used to assess for 
non-linearity. The normality assumption requires that the residuals are normally distributed, 
which was assessed using quantile-quantile (Q-Q) plot. The homoscedasticity assumption 
requires that the error variance be constant, which was assessed using residual-versus-fitted plot. 
Lastly, the variance inflation factor (VIF) was used to test for multicollinearity. A VIF of 10 was 
used as the rule of thumb to indicate an acceptable level of multicollinearity166.  
4.6.6 Multivariable Regression Analysis  
Inferential statistical analysis was performed to generalize about the population from which the 
sample was taken167. Valid inference means that the standard errors of the parameter estimate are 
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valid, confidence intervals have the desired coverage probability and p-values correctly describe 
the probability of observing the absolute value of the observed parameter estimate168.  
Multivariable linear and logistic regression analyses were performed using STATA 13. 
4.6.6.1 Multivariable Linear Regression 
A multivariable linear regression model was built to identify the predictor variables associated 
with the following two outcomes: social support and community integration; and VRQoL. 
Multivariable linear regression models the relationship between a set of predictor variables on 
the likelihood of one continuous outcome, by fitting a linear equation to the observed data.  
The equation for systematic part of the model is:  !(#|%) = () + (+%+ + (,%, + ⋯+ (.%. 
where !(#|%) is the expected value of the outcome at a given value of a set of predictor variables 
 %/ (i = 1, 2, … n) are the predictor variables 
 () is the intercept 
 (/ (i = 1, 2, … n) are the slopes for each variable (i.e., regression coefficients) 
The intercept, (()), denotes the probability of the outcome when %/ = 0, which can be 
interpretable by “centering” the continuous predictor variables. For the continuous predictor 
variables, the coefficient,  (/ ,is interpreted as the change in the expected outcome for a one unit 
increase in one predictor variable, while holding all other predictor variables in the model 
constant. For categorical predictor variables, we get the probability of the outcome in the group 
with respect to the reference group, adjusting for all other predictor variables.  
There is also a random part of the model, in which each observation of the outcome is modeled 
in terms of an error term168. 
The equation for the random part of the model is: 
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#/ = ! #/ %/ + e/ = 	() + (+%+/ + (,%,/ + ⋯+ (.%./ + e/ 
where e/ is the error term about an average determined by %/ 
 %1/ (i = 1, 2, … n) is the value of the predictor variable %1 for observation i 
We assume that e/	is normally distributed with a mean of zero.  
Linear regression diagnostics were checked to ensure the data met the assumptions of linear 
regression and to avoid potential bias of the parameter estimates. Normality of residuals was 
assessed using residual plots. Homogeneity of variance of the residuals (homoscedasticity) was 
assessed using a residual-versus-fitted plot. Multicollinearity was assessed using variance 
inflation factor (VIF). Linearity was assessed for each continuous predictor variable using 
component-plus-residual plots. Specification error was tested using a link test. 
4.6.6.2 Multivariable Logistic Regression  
A logistic regression model was built to identify the predictor variables associated with the 
following two outcomes: presence of depressive symptoms and preference based HRQoL. 
Logistic regression models the effect of a set of predictor variables on the likelihood of one 
binary outcome.  
The equation for multivariable logistic regression is:  23456 7/ = () + (+8+ + (,8, + ⋯+ (.8. 
where 7/ is the probability of the outcome 
 8/ (i = 1, 2, … n) are the predictor variables 
 () is the intercept 
 (/ (i = 1, 2, … n) are the regression parameters 
 23456 is the ln (odds of the outcome), where odds is ( 9:+;9:) 
  
 
 
48 
The intercept (()) denotes the log of the odds of the outcome when all 8/ = 0, which may or may 
not contain meaningful interpretation, but is still an integral part of the model. We obtain the 
odds of the outcome when  8/ = 0 by exponentiating the intercept. By exponentiating the 
regression coefficient ((/), we get the odds ratio of the outcome. For the continuous predictor 
variables, exponentiating the coefficient will provide the odds ratio of the outcome for every one 
unit increase in 8/, adjusting for all other predictor variables. For categorical predictor variables, 
we get the odds ratio of the outcome comparing the higher category of 8/ to its reference 
category, adjusting for all other predictor variables.  
Logistic regression diagnostics were checked to ensure linear relationship with the logit of the 
outcome and absence of multicollinearity. Linearity between the continuous predictor variables 
and the logit of the outcome was assessed using scatter plots. Multicollinearity was previously 
assessed using VIF. 
4.6.7 Variable Selection for Building Prediction Models  
The primary aim of prediction is to minimize error rather than identifying associations168. 
Variable selection for prediction purposes is intended to select the best set of predictor variables. 
In terms of prediction, variable selection is valuable so that we can save time and money by not 
measuring redundant predictor variables. The aim is to construct a model that predicts the value 
of the outcome given the predictor variable. Stepwise regression and Classification and 
Regression Tree (CART) are machine learning approaches to variable selection. 
Some predictor variables are well-established in literature as being highly associated with the 
outcome, thus predictor variables may be included in the model for face validity without 
considering the strength or statistical significance168. Selecting predictor variables based on p-
values have been criticized, since no significance of an effect is not equal to the absence of an 
effect168.  Variable selection is important as it aims to determine which variables are strong 
predictor variables of the outcome and to find the right balance between goodness of fit and 
parsimonious model. Variable selection can improve interpretability and accuracy of the 
predictions. A parsimonious model is one that achieves a desired level of prediction with as few 
predictor variables as possible. 
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With building the “best” predictive model, the issue lies in having to choose predictor variables 
from a larger set169. It is not just sufficient to perform automatic statistical variable selection, but 
it is important to consider clinical significance as well. 
4.6.7.1 Stepwise Regression 
There are several different methods used to select predictor variables when fitting a regression 
model. Forward selection starts with no predictor variables in the model and then tests the 
addition of each predictor variable. Backward elimination starts with all predictor variables in the 
model and then tests the removal of each predicator variable. Stepwise regression is combination 
of forward selection and backward elimination. It is an automated approach used in exploratory 
model building to select predictor variables. During this method, predictor variables are 
systematically added and/or removed, beginning with a model that has all the variables in it. The 
predictor variables that are dropped during stepwise regression may still be correlated with the 
outcome, but provide no additional explanatory effect beyond the predictor variables already 
included in the model168. The number of possible models is dependent on the number of 
predictor variables170. For example, five predictor variables yield 25 = 35 possible regression 
models. These models are fit based on a criterion, from which the best model is chosen. 
Automatic methods are useful when there are many predictor variables and it is not feasible to fit 
all possible models. 
Information criteria is a measure of goodness of fit that takes into account both predictive 
accuracy and model complexity. Under-fitting a model may not capture the true variability of the 
outcome, and over-fitting a model can lose generalizability. Akaike Information Criterion (AIC) 
was introduced as a tool for optimal model selection: <=> = −2ℓ + 2B 
where 		ℓ  is the maximized log-likelihood 													B  is the number of parameters included in the model 
AIC considers both the model fit and number of predictor variables used, it is not a p-value 
driven approach. The AIC value is measured as the likelihood of the parameters estimates being 
correct for the population based on the observed data. Stepwise regression with AIC 
  
 
 
50 
simultaneously evaluates a subset of possible multiple regression models to find the best 
model171. AIC measures the balance between the amount of explanatory power and the model 
size. The model with the smallest AIC value is determined as the better model.  
We performed stepwise model selection by AIC using R (package ‘MASS’)172. 
4.6.7.2 Classification and Regression Trees 
CART analysis is a machine learning method used to create a decision tree that predicts the 
outcome based on several predictor variables and helps to determine the “most” important 
predictor variables of the outcome. It is a visual representation of the relationship among the 
important predictor variables and the outcome. Classification tress are for binary outcomes and 
regression trees are for continuous outcomes173. The goal is to use a training sample of 
observations and find a model to predict values of the outcome from new values of the predictor 
variables173. CART also captures interaction effects between predictor variables. 
The basic structure and splitting algorithm of CART is shown in Figure 4-1: 
 
Figure 4-1. The basic structure and splitting algorithm of Classification and Regression 
Trees 
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Each node is conditioned on a predictor variable,	%/ ,  starting at the root node. The final split is 
called the leaf node and the terminal node, ax , indicates that further splitting of the data does not 
have enough variance to explain the outcome. CART is built using a splitting algorithm that 
splits the data into smaller parts based on yes/no questions with maximum homogeneity174. 
Maximum homogeneity is defined by an impurity function (5(6)).  
Gini Index is the impurity function commonly used for classification trees. The Gini Index 
defines the node splits, where each split maximizes the decrease in impurity173: 
5 6 = 1 − B,(D|6)EFG+  
where 		D	is the index of the class B(D|6) is the conditional probability of class D in node 6  
Regression trees do not have classes, instead response vectors of the outcome are used. Like the 
Gini index, for regression trees the splitting is made according to the squared residuals 
minimization algorithm173: H5IJ:KJ:L[NOPQR SO + NTPQR ST ] 
where PQR SO , PQR ST  is the response vector for the left and right internal nodes 
 %/ ≤ %/X (5	= 1, 2 … n) is the optimal splitting rule 
A larger initial tree was created with recursive partitioning, where a split was determined by 
examining all possible split values for each variable to find the best split.  Then the tree was 
pruned with a cross-validation method, to create an optimal tree and minimize misclassification 
error. To validate the tree a cost-complexity parameter (CP) is used. The least CP value indicates 
that the cross-validated error of the tree is minimum to determine true predictive power of the 
tree. The CP function is175:  Ya Z = 	Y Z + a|Z| 
where T  is the number of terminal nodes or complexity of the tree 
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												Y Z 	 is the resubstitution misclassification error of the tree T 
|Z|		is the number of terminal (or “leaf”) nodes in the tree 
									a|Z|		is the complexity measure that depends on Z for a given value	a 
CART analysis was performed using the ‘rpart’ package implemented in R (package ‘rpart’). By 
default, ‘rpart’ conducts as many splits as possible, then uses 10-fold cross-validation to prune 
the tree.   
4.6.8 Model Assessment 
Model assessment is based on the models ability to accurately predict new data (i.e., prediction) 
and whether the model accurately describes the associations in the current data (i.e., goodness of 
fit)168.  
To avoid results by chance, the data can be split several different times to create two data sets – 
training and validation176. The validation set is used to estimate the error rate of the training set. 
Assessing the average performance of a model over the different splits is referred to as cross-
validation. Cross-validation is a model validation technique for assessing how the results will be 
generalizable. It is mainly used to estimate how accurately a model will perform and compare the 
performance of different models. 
 
Since the data set had 250 observations, we chose to perform leave-one-out cross validation 
(LOOCV), where a single observation is used for the validation set and n-1 is used for the 
training set177.  This procedure is repeated so that each observation in the original data set has 
been a part of the validation set. LOOCV evaluates a model based on prediction and is used for 
estimating the test error176. In comparison to k-fold cross validation, the LOOCV approach has 
less bias and does not overestimate the test error rate, since the training sets used contain n-1 
observations177. The LOOCV estimate for the mean squared error (MSE) is the average of I test 
error estimates177: 
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[\\>P. = 1I ]^!/./G+  
where ]^!/ is represented by (#/ − #/), and #/ is the prediction made for the excluded 
observation. 
 
The absolute error (AE) is the difference between the measured and actual values. The mean 
absolute error (MAE), standard error (SE) and standard deviations (SD) were used to summarize 
the errors and describe the predictive performance of each model. MAE is a good indicator of 
average model performance and is widely used in model evaluation178. The MAE is calculated 
as: ]<! = 1I |_/|./G+  
where _/ (5 = 1, 2, … , I) is the n samples of model errors produced by LOOCV 
 n is the sample size 
 
SE quantifies the variability of estimated parameters for precision, whereas SD measures the 
variability of the data from the mean179. SD of the AE is defined as: 
^abc = 1I − 1 ( _/ , − ]<!),./G+  
 
The underlying assumption with SE is that the errors are unbiased and follow a normal 
distribution, which provides a representation of the error distribution. SE of the estimate of MAE 
is calculated as:  ^!dbc = ^abcI  
 
4.6.9 Software 
All preliminary and main analysis were executed using STATA 13 and R (version 1.0.136) 
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Chapter 5  
5 Results  
This chapter first presents the characteristics of the study population and the results of imputation 
(Section 5.1 and 5.2). Following is a discussion of the associations among the predictor variables 
(Section 5.3) and a statement of the regression diagnostics performed (Section 5.4). 
Section 5.5 provides an overview of all the analyses conducted –bivariate analysis, multivariable 
regression analysis, stepwise regression, Classification and Regression Trees (CART), and 
model assessment. Section 5.6 presents the results for each of the four PROs – social support and 
community integration, presence of depressive symptoms, vision-related quality of life (VRQoL) 
and preference-based HRQoL. 
5.1 Characteristics of the Study Population  
Univariate analysis was performed to determine the characteristics of the study population. A 
total of 250 patients consented to participate in the study. The patients’ demographic 
characteristics are presented in Table 5-1. The average age of the study population [mean (SD)] 
was about 72.9 (10.2) years. The sex distribution was 60% female. The majority of patients were 
Caucasian (80%) and lived at home with their family, spouse or caregiver (69%). About half had 
completed high school or less (49%) and about 40% had an income of less than $25,000. Only 
about 11% used a mobility aid such as a cane, walker, wheelchair or motorized scooter.  
The patient’s clinical characteristics are presented in Table 5-2. The majority of patients had 
mild vision loss (72%) based on the best corrected visual acuity (BCVA) in the worse-seeing eye 
and received medication as their initial treatment (72%). About 33% of the patients were 
diagnosed as glaucoma suspects and only about 15% were diagnosed with severe glaucoma. The 
average number of comorbidities in the study population [mean (SD)] was 1.6 (1.5), average 
number of ocular conditions was 2.1 (1.1), average number of ocular procedures was 1.1 (1.0) 
and average time since diagnosis was 100.7 (74.5) months. 
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5.2 Missing Data 
Imputation of the missing values for the income variable was performed and the distribution of 
the pre-imputed values did not greatly differ from the distribution of the post-imputed values 
(Table 5-3). 
5.3 Associations Among Predictor Variables  
5.3.1 Association Between Pairs of Continuous Predictor Variables 
The results of the associations between continuous predictor variables are presented in Table 5-4. 
Pearson correlations did not reveal any strong linear associations among the continuous predictor 
variables: age, number of comorbidities, number of ocular condition, number of ocular 
procedures and time since diagnosis. 
5.3.2 Associations Between Pairs of Categorical Predictor Variables   
The chi-square test results of the associations between categorical predictor variables are 
presented in Table 5-5. Significant associations were observed between sex and income. A 
greater number of females (46%) had an income of less than $25 000. Sex was also significantly 
associated with living arrangement. A greater number of males (77%) were living at home with 
others. A significant association was observed between education and use of mobility aid. About 
half of the patients who did not use mobility aids, had completed more than high school (54%). 
BCVA was found to be significantly associated with the use of mobility aid and glaucoma stage. 
Among the patients who did not use mobility aids, significantly more patients had mild visual 
acuity loss (92%), compared to only 9% who had severe glaucoma. 
5.3.3 Associations Between Pairs of Continuous and Categorical Predictor 
Variables 
The t-test and one-way ANOVA results for the associations between continuous and categorical 
predictor variables are presented in Table 5-6. Age was significantly associated with income, 
living arrangement, use of mobility aid, BCVA and glaucoma stage. On average, patients with an 
income of less than $25 000, living in a nursing or retirement home, using a mobility aid, 
moderate visual acuity loss and severe glaucoma were slightly older. Number of comorbidities 
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was significantly associated with sex. Number of ocular conditions was significantly associated 
with BCVA. Number of ocular procedures was significantly associated glaucoma stage and 
initial treatment. Time since diagnosis was significantly associated with initial treatment. On 
average, patients who had medication as their initial treatment, had a higher number of ocular 
procedures and greater time since diagnosis.  
5.4 Regression Diagnostics 
The component-plus-residual plots, Q-Q plots, residual-versus-fitted plots and the variance 
inflation factors confirmed the assumption of linearity, normality, homoscedasticity and 
multicollinearity, respectively.  
5.5 Overview of the Statistical Analyses 
5.5.1 Bivariate Analysis for Unadjusted Effects 
The bivariate analysis results for social support and community integration; presence of 
depressive symptoms, VRQoL and preference-based HRQoL with the demographic and clinical 
predictor variables are presented in Tables 5-7 and 5-8; 5-13 and 5-14; 5-19 and 5-20; 5-25 and 
5-26, respectively. There was a total of 13 predictor variables included, of which six were 
demographic and seven were clinical variables. A significance level of p £ 0.05 was used to 
determine variables that were significantly associated with the PRO. 
5.5.2 Multivariable Regression Analysis for Adjusted Effects 
Multivariable regression analysis results for social support and community integration; presence 
of depressive symptoms, VRQoL and preference-based HRQoL are presented in Tables 5-9, 5-
15, 5-21 and 5-27, respectively. All predictor variables identified through review of the 
literature, expert opinion and conceptual model were included in the multivariable analyses. A 
significance level of p £ 0.05 was used to determine variables that were significantly associated 
with the outcome. 
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5.5.3 Variable Selection for Developing Prediction Models 
5.5.3.1 Stepwise Regression 
Stepwise regression by Akaike Information Criterion (AIC) for social support and community 
integration; presence of depressive symptoms, VRQoL and preference-based HRQoL are 
presented in Tables 5-10, 5-16, 5-22 and 5-28, respectively. The selected model was based on the 
lowest AIC value.    
5.5.3.2 Classification and Regression Trees 
Classification and Regression Tree (CART) is an effective machine learning technique, 
commonly used for developing prediction models180. Classification trees are used for categorical 
outcomes and regression trees are used for continuous outcomes. Recall that CART qualitatively 
expresses the relationship between the predictor variables and each outcome by repeatedly 
splitting the data based on one predictor variable. At each split the data is divided into two 
groups174. The objective is to create a reasonably small tree to avoid overfitting the data and 
identify the relevant predictor variables. To avoid overfitting, after the splitting procedure creates 
the initial tree with the maximum number of splits, the tree is pruned to obtain the optimal tree 
with the most important variables. When a pruned tree results in zero splits, this suggests that 
there isn’t enough signal within the data to justify a tree model.  
5.5.4 Model Assessment for Developing Prediction Models 
The leave-one-out cross validation (LOOCV) method was used to assess the predictive 
performance of each outcome. The mean absolute error (MAE), standard error (SE) and standard 
deviation (SD) for the models built for social support and community integration; presence of 
depressive symptoms; VRQoL and preference-based HRQoL are presented in Tables 5-12, 5-18, 
5-24 and 5-30, respectively. In addition to the four variable selection methods (selected 
multivariable regression, stepwise regression, initial CART and pruned CART), the initial 
multivariable regression model and the baseline model were assessed for comparison. The 
baseline model, with only the intercept, is the worst possible model. First, the model with the 
lowest MAE was selected, and all plausible models were selected if it was within one SE from 
the lowest MAE. Of all plausible models, the most promising model was determined based on 
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the model with the lowest number of variables selected. This procedure for selecting the most 
promising model was followed by the methodology outlined by Hastie et al. (2008)128.  
5.6 Results for Each Patient-Reported Outcome 
5.6.1 Social Support and Community Integration  
Recall, that the Community Integration Questionnaire (CIQ) score was used to measure social 
support and community integration on a scale from 0 to 29, in which a higher score represents 
complete community integration and a higher level of social support. In our study population, the 
average CIQ total score was 17.9±5.0, with a minimum average score of two and maximum of 
28. Thus, majority of the patients had moderate social support and community integration.    
5.6.1.1 Unadjusted Effects of Social Support and Community Integration 
The bivariate analysis for social support and community integration with the demographic 
variables is presented in Table 5-7, and for clinical variables it is presented in Table 5-8. The 
following five demographic variables were significantly associated with social support and 
community integration: age (p < 0.0001), sex (p < 0.0001), income (p < 0.0001), living 
arrangement (p<0.0001), and use of mobility aid (p < 0.0001). On average, for every year 
increase in age, the expected social support and community integration decreases by 0.17±0.03 
(95% CI = -0.22 to -0.11). On average, males are expected to obtain a lower social support and 
community integration than females (-3.18±0.61, 95% CI = -4.39 to -1.97). Patients with an 
income between $25 000 to $50 000 (2.17±0.76, 95% CI = 0.66 to 3.67) and greater than $50 
000 (2.95±0.77, 95% CI = 1.44 to 4.47), on average, are expected to obtain social support and 
community integration that is greater than patients with income less than $25 000. On average, 
patients living at home with others (-1.97±0.67, 95% CI = -3.30 to -0.65) and living in a 
nursing/retirement home (-9.26±2.48, 95% CI = -14.15 to -4.38), are expected to obtain social 
support and community integration that is lower than patients living at home alone. Patients 
using a mobility aid, on average, are expected to obtain social support and community 
integration that is lower than patients who do not use a mobility aid (-4.96±0.95, 95% CI = -6.84 
to -3.09).  
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The only clinical variable that was found to be significantly associated with social support and 
community integration was moderate visual acuity loss (p = 0.01). On average, patients with 
moderate visual acuity loss are expected to obtain social support and community integration that 
is lower than patients with mild visual acuity loss (-2.23±0.89, 95% CI = -3.98 to -0.47). 
5.6.1.2 Adjusted Effects Social Support and Community Integration 
The estimated coefficients and p-values from the multivariable linear regression analysis with 
social support and community integration as the dependent variable are presented in Table 5-9. 
The five variables that were found to be significant with social support and community 
integration are: age (p < 0.0001), sex (p < 0.0001), income (p < 0.0001), living arrangement (p < 
0.0001) and use of mobility aid (p = 0.003). Adjusting for all predictor variables, for every year 
increase in age, on average the expected social support and community integration decreases by 
0.15±0.03 (95% CI= -0.21 to -0.09). On average, males are expected to obtain a lower social 
support and community integration than females (-3.28±0.56, 95% CI= -4.38 to -2.18). Patients 
with an income greater than $50 000, on average, are expected to obtain social support and 
community integration that is greater than patients with income less than $25 000 (3.07±0.66, 
95% CI= 1.77 to 4.37). Patients living at home with others (-2.58±0.59, 95% CI=-3.75 to -1.41) 
and in nursing home or retirement home (-7.92±2.12, 95% CI= -12.09 to -3.74), on average, are 
expected to obtain social support and community integration that is lower than patients who are 
living at home alone. Patients using a mobility aid, on average, are expected to obtain social 
support and community integration that is lower than patients who do not use a mobility aid (-
2.63±0.87, 95% CI= -4.34 to -0.92). 
No clinical variables were found to be significantly associated with the CIQ score. When 
controlling for all variables, age, sex, living arrangement and use of mobility aid had a negative 
relationship with social support and community integration, and income had a positive 
relationship. The overall model was significant (p < 0.0001), with a generalized R-squared of 
0.42, suggesting that 42% of the variance in CIQ score is explained by this multivariable 
regression model.  
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5.6.1.3 Stepwise Regression for Social Support and Community 
Integration 
The results from stepwise regression analysis by AIC for social support and community 
integration is presented in Table 5-10. The initial model for social support and community 
integration consisted of the 13 predictor variables and had an AIC value of 706.19. The final 
model with the lowest AIC value of 690.61, consisted of the following five predictor variables: 
age, sex, income, living arrangement and use of mobility aid. 
5.6.1.4 Regression Tree for Social Support and Community Integration 
The initial regression tree of social support and community integration is presented in Figure 5-1, 
where the data were split (root node) using the variable ‘use of mobility aid’ and the final split 
(leaf node) contained the predicted score obtained from the CIQ, ranging from 0 to 29. For 
example, a patient who does not use mobility aid, is a male and is not ³ 62 years of age, has a 
predicted score of 21 (range = 0 to 29). The initial regression tree has 12 nodes, whereas the 
pruned tree in Figure 5-2 has only three nodes.  
 
 
 
 
 
 
 
 
 
   
Figure 5-1. Initial regression tree for social support and community integration 
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Figure 5-2. Pruned regression tree for social support and community integration 
5.6.1.5 Variable Selection for Social Support and Community Integration 
The selected variables from multivariable regression, stepwise regression by AIC, initial and 
pruned CART analyses for predicting social support and community integration are presented in 
Table 5-11. Eight variables were selected from the initial CART analysis, five variables were 
selected from multivariable and stepwise regression by AIC and three variables were selected 
from the pruned CART analysis.  Age, sex and use of mobility aid were selected from all four 
methods. Income and living arrangement were selected from two of the four methods. Education, 
number of comorbidities, number of ocular conditions and number of ocular procedures were not 
selected from any of the methods. Thus, the main predictor variables explaining patients social 
support and community integration among our patient populations seems to be age, sex and use 
of mobility aids. 
5.6.1.6 Model Assessments for Social Support and Community 
Integration 
The model with the lowest MAE for the social support and community integration outcome is 
stepwise regression model by AIC, with a MAE of 3.21. The plausible models are the models 
with a MAE of 3.37 or less, which include: initial multivariable regression model and selected 
multivariable regression model. From Table 5-12, of the plausible models, the model with the 
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lowest number of predictor variables is the selected multivariable and stepwise regression model. 
Therefore, the most promising predictor variables of social support and community integration 
are presented in the model below: 
Social support and community integration = α + β1 (age) + β2 (sex) + β3 (income) + β4 
(living arrangement) + β5 (use of mobility aid) 
5.6.2 Presence of Depressive Symptoms 
Recall, that the Patient Health Quesionnaire-9 (PHQ-9) total score was dichotomized as ‘no 
depressive symptoms’ and ‘some depressive symptoms’ (refer to Section 4.5.2). Among the 
study population, about 79% reported having no depressive symptoms. In other words, on the 
original PHQ-9 scale (score range: 0 to 27), 79% of the patients reported a score of four or less.  
5.6.2.1 Unadjusted Effects of the Presence of Depressive Symptoms 
The bivariate analysis for the presence of depressive symptoms with the demographic variables 
is presented in Table 5-13, and for clinical variables it is presented in Table 5-14. The following 
four demographic variables were significantly associated with the presence of depressive 
symptoms: income (p = 0.04), education (p < 0.0001), living arrangement (p = 0.04), and use of 
mobility aid (p < 0.0001). Patients with an income greater than $50 000 (OR = 0.43, 95% CI = 
0.19 to 0.96), on average, were less likely to report having depressive symptoms than patients 
with income less than $25 000. On average, patients who completed more than high school were 
less likely to report having depressive symptoms than patients who completed high school or less 
(OR = 0.50, 95% CI = 0.27 to 0.93). Patients who used mobility aid, on average, were more 
likely to report having depressive symptoms than patients who did not use mobility aid (OR = 
3.31, 95% CI = 1.46 to 7.53).  
Initial treatment (p < 0.0001) was the only clinical variable that showed significant association 
with the presence of depressive symptoms. 
5.6.2.2 Adjusted Effects of the Presence of Depressive Symptoms 
The estimated odds ratio and p-values from the multivariable logistic regression analysis with the 
presence of depressive symptoms as the dependent variable, are presented in Table 5-15. Two 
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variables were significantly associated with the presence of depressive symptoms: use of 
mobility aid (p = 0.006) and initial treatment (p = 0.01). Patients who used a mobility aid were 
more likely to report having depressive symptoms than patients who did not use a mobility aid 
(OR=4.37, 95% CI=1.59 to 12.05). Patients who had selective laser trabeculoplasty as their 
initial treatment (OR=3.52, 95% CI=1.42 to 8.75) and no initial treatment (OR=3.24, 95% 
CI=1.02 to 10.27) were more likely to report having depressive symptoms than patients who had 
medication as their initial treatment.  
The generalized R-squared is not interpreted the same way for logistic regression, as it is in 
linear regression. Rather, the pseudo R-squared measure is used in logistic regression and it is 
defined as the following: 
1 −	 log 25D_25ℎ33i	3j	6ℎ_	jk22	H3i_2, l56ℎ	6ℎ_	5I6_Rm_B6log 25D_25ℎ33i	3j	6ℎ_	H3i_2	l56ℎ	3I2#	6ℎ_	5I6_Rm_B6 
The pseudo R-squared corresponds to a proportional reduction in the error variance181. The 
overall model for the presence of depressive symptoms was significant (p = 0.04), with a pseudo 
R-squared of 0.16. 
5.6.2.3 Stepwise Regression for the Presence of Depressive Symptoms 
The stepwise regression analysis by AIC for the presence of depressive symptoms is presented in 
Table 5-16.  The initial model for presence of depressive symptoms consisted of the 13 predictor 
variables and had an AIC value of 258.39. The final model with the lowest AIC value of 247.71, 
consisted of the following seven predictor variables: age, sex, education, living arrangement, use 
of mobility aid, number of comorbidities and initial treatment. 
5.6.2.4 Classification Tree for Presence of Depressive Symptoms  
The initial classification tree for presence of depressive symptoms is presented in Figure 5-3, 
where the data were split (root node) using the variable ‘use of mobility aid’ and the final split 
(leaf node) contained the predicted probability of having depressive symptoms (0 = no 
depressive symptoms). For example, a patient who does not use mobility aids, who’s initial 
treatment is medication, is ³ 62 years of age and time since diagnosis is < 138 months, was 
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predicted to have a 0.077 probability of having depressive symptoms. The initial classification 
tree has 12 nodes, and pruning the tree resulted in zero splits. 
 
5.6.2.5 Variable Selection for Presence of Depressive Symptoms  
The selected variables from multivariable regression, stepwise regression by AIC, initial and 
pruned CART analyses for predicting the presence of depressive symptoms is presented in Table 
5-17. Eight variables were selected from stepwise regression and seven from the initial CART 
analysis. Two variables were selected from multivariable regression analysis. No variables were 
Figure 5-3.Initial classification tree for presence of depressive symptoms 
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selected by the pruned CART analysis. Initial treatment was selected from all four methods. Use 
of mobility and initial treatment were selected from three of the four methods. BCVA, number of 
ocular conditions, number of ocular procedures and glaucoma stage were not selected from any 
of the methods. Thus, the main predictor variables explaining the presence of depressive 
symptoms among our patient population were use of mobility aids and initial treatment. 
5.6.2.6 Model Assessment for the Presence of Depressive Symptoms  
The model with the lowest MAE for the presence of depressive symptoms is stepwise regression 
model by AIC, with a MAE of 0.30. The plausible models are the models with a MAE of 0.32 or 
less, which include: initial multivariable regression model, selected multivariable regression 
model and initial classification tree. From Table 5-18, of the plausible models, the model with 
the lowest number of predictor variables is the selected multivariable regression model. 
Therefore, the most promising predictor variables for the presence of depressive symptoms are 
presented in the model below: 
Depressive symptoms = α + β1 (use of mobility aid) + β2 (initial treatment) 
5.6.3 Vision-Related Quality of Life 
Recall, that the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was used 
to assess the vision-related quality of life (VRQoL) among the study population. The overall 
composite score ranged from 0 to 100, where 100 is the best possible score. On average, the 
patients reported a composite score of 88.7±12.4, with a minimum average score of 9.8 and 
maximum of 100. Thus, majority of the patients had a fairly high VRQoL.  
5.6.3.1 Unadjusted Effects of Vision-Related Quality of Life 
The bivariate analysis for VRQoL with the demographic variables are presented in Table 5-19, 
and for clinical variables it is presented in Table 5-20. The two demographic variables associated 
with VRQoL were income (p = 0.006) and use of mobility aids (p < 0.0001). On average, 
patients with an income greater than $50 000, are expected to obtain VRQoL that is greater than 
patients with income less than $25 000 (5.19±1.89, 95% CI = 1.48 to 8.91). Patients who use 
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mobility aids, on average, are expected to obtain VRQoL that is less than patients who do not use 
a mobility aids (-11.49±2.37, 95% CI = -16.16 to -6.81).    
The two clinical variables associated with VRQoL were BCVA in the worse-seeing eye (p < 
0.0001) and number of ocular conditions (p = 0.004). On average, patients with moderate visual 
acuity loss (-9.00±1.91, 95% CI = -12.76 to -5.25) and legal blindness (-18.44±2.03, 95% CI = -
22.43 to -14.45), are expected to obtain VRQoL that is less than patients with mild visual acuity. 
On average, for each increase in number of ocular conditions, the expected VRQoL decreases by 
2.05±0.71 (95% CI = -3.44 to -0.65). 
5.6.3.2 Adjusted Effects of Vision-Related Quality of Life 
The estimated coefficients and p-values from the multivariable linear regression analysis with 
VRQoL as the dependent variable is presented in Table 5-21. The following three demographic 
and one clinical variables were significantly associated with VRQoL: income (p = 0.01), living 
arrangement (p = 0.03), use of mobility aid (p < 0.0001) and BCVA in the worse-seeing eye (p < 
0.0001). When controlling for all variables, living arrangement, use of mobility aids, BCVA in 
the worse-seeing eye had a negative relationship with VRQoL and income had a positive 
relationship.  
Patients with an income greater than $50 000, on average are expected to obtain VRQoL that is 
greater than patients income less than $25 000 (3.99±1.63, 95% CI= 0.78 to 7.19). Patients living 
in a nursing or retirement home, on average, are expected to obtain VRQoL that is lower than 
patients living at home alone (-22.49±5.24, 95% CI= -32.82 to -12.16). Patients using mobility 
aids, on average, are expected to obtain VRQoL that is lower than patients not using mobility 
aids (-7.62±2.15, 95% CI= -11.85 to -3.39). Patients with a moderate visual acuity loss (-
8.20±1.92, 95% CI= -11.97 to -4.42) and legal blindness (-17.03±2.02, 95% CI= -21.02 to -
13.05), on average, are expected to obtain VRQoL that is lower than patients with mild visual 
acuity loss.  
The overall model was significant (p < 0.0001), with a generalized R-squared of 0.40, suggesting 
that 40% of the variance in NEI VFQ-25 score is explained by this multivariable regression 
model. 
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5.6.3.3 Stepwise Regression for Vision-Related Quality of Life 
The stepwise regression analysis by AIC for the presence of VRQoL is presented in Table 5-22. 
The initial model for VRQoL consisted of the 13 predictor variables and had an AIC value of 
1167.55. The final model with the lowest AIC value of 1152.89, consisted of the following five 
predictor variables: income, living arrangement, use of mobility aid, BCVA in the worse-seeing 
eye and number of ocular conditions.   
5.6.3.4 Regression Tree for Vision-Related Quality of Life 
The initial regression tree of VRQoL is presented in Figure 5-4, where the data were split (root 
node) using the variable ‘BCVA’ and the final split (leaf node) contained the predicted NEI 
VFQ-25 score ranging from 0 to 100. For example, a patient whose BCVA is categorized as 
moderate visual acuity loss or legal blindness and uses mobility aid, has a predicted score of 67 
(range = 0 to 100). The initial regression tree has five nodes, whereas the pruned tree in Figure 5-
5 has only one node.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4. Initial regression tree for vision-related quality of life 
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Figure 5-5. Pruned regression tree for vision-related quality of life 
5.6.3.5 Variable Selection for Vision-Related Quality of Life 
The selected variables from multivariable regression, stepwise regression by AIC, initial and 
pruned CART analyses for predicting VRQoL is presented in Table 5-23. Five variables were 
selected from stepwise regression and the initial CART analysis. Four variables were selected 
from multivariable regression and one variable was selected from the pruned CART analysis. 
BCVA was selected from all four methods. Income and use of mobility aids were selected from 
three of the four methods. Sex, education, number of comorbidities, number of ocular 
procedures, time since diagnosis and initial treatment were not selected from any of the methods. 
The main predictor variable explaining VRQoL is BCVA in the worse-seeing eye.  
5.6.3.6 Model Assessments for Vision-Related Quality of Life 
The model with the lowest MAE is the pruned regression tree, with a MAE of 6.77. The 
plausible models are the models with a MAE of 7.33 or less, which include: initial multivariable 
regression model, selected multivariable regression model, stepwise regression model and initial 
regression tree. From Table 5-24, of the plausible models, the model with the lowest number of 
predictor variables is the pruned regression tree. Therefore, the most promising predictor 
variables of VRQoL is presented in the mode below: 
VRQoL = α + β1 (BCVA in the worse-seeing eye) 
5.6.4 Preference-Based Health-Related Quality of Life 
Recall, that the Time Trade-Off (TTO) technique was used to measure the patients’ preference-
based HRQoL and the utility value was dichotomized to “not willing to give up any years of life” 
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and “willing to give up some years of life” (refer to Section 4.5.4). Among the study population, 
about 71% were not willing to give up any years of life for perfect vision. Thus, majority of the 
patients had a high preference-based HRQoL. 
5.6.4.1 Unadjusted Effects of Preference-Based Health-Related Quality 
of Life  
The bivariate analysis for preference-based HRQoL with the demographic variables are 
presented in Table 5-25, and for clinical variables in Table 5-26. One demographic and two 
clinical variables were significantly associated with preference-based HRQoL: education (p < 
0.0001), legal blindness (p = 0.009) and number of ocular conditions (p = 0.02). Patients with 
legal blindness, on average, were more willing to give up some years of like for perfect vision 
than patients with mild visual acuity loss (OR = 2.81, 95% CI = 1.29 to 6.14).  On average, 
patients were more willing to give up some years of life for perfect vision with increasing 
number of ocular conditions (OR = 1.37, 95% CI = 1.06 to 1.76). 
5.6.4.2 Adjusted Effects of Preference-Based Health-Related Quality of 
Life  
The estimated odds ratio and p-values from the multivariable logistic regression analysis with 
preference-based HRQoL as the dependent variable is presented in Table 5-27. Two clinical 
variables were found to be significantly associated with preference-based HRQoL: BCVA in the 
worse-seeing eye (p = 0.01) and number of ocular conditions (p = 0.04). No demographic 
variables were found to be significantly associated.  
Patients with legal blindness were more willing to give up some years of life for perfect vision 
than patients with mild visual acuity loss (OR=3.10, 95% CI= 1.27 to 7.57). Patients were more 
willing to give up some years of life for perfect vision with increasing number of ocular 
conditions (OR=1.35, 95% CI= 0.60 to 3.04). 
The overall model was not significant (p = 0.24), with a pseudo R-squared of 0.09. 
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5.6.4.3 Stepwise Regression for Preference-Based Health-Related 
Quality of Life 
The stepwise regression analysis by AIC for the presence of preference-based HRQoL is 
presented in Table 5-28. The initial model for preference-based HRQoL consisted of the 13 
predictor variables and had an AIC value of 312.88. The final model with the lowest AIC value 
of 294.68, consisted of the following four predictor variables: age, education, BCVA worse-
seeing eye and number of ocular conditions.   
5.6.4.4 Classification Tree for Preference-Based Health-Related Quality 
of Life 
The initial classification tree for preference-based HRQoL is presented in Figure 5-6, where the 
data were split (root node) using the variable ‘age’ and the final split (leaf node) contained the 
predicted probability of giving up any years of life for perfect vision (0 = not willing to give up 
any years of life). For example, a patient who is ³ 76 years of age, BCVA is categorized as mild 
VA loss and has < 2.5 ocular procedures, is predicted to have a 0.11 probability of giving up 
years of life for perfect vision. The initial classification tree has 15 nodes, and pruning the tree 
resulted in zero splits.   
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5.6.4.5 Variable Selection for Preference-Based Health-Related Quality 
of Life 
The selected variables from multivariable regression, stepwise regression by AIC, initial and 
pruned CART analyses for predicting preference-based HRQoL is presented in Table 5-29. Ten 
variables were selected from the initial CART analysis. Four variables were selected from the 
stepwise regression analysis. Two variables were selected from the multivariable regression 
analysis. No variables were selected from the pruned CART analysis. BCVA and number of 
ocular conditions were selected from two of the four methods. Sex, income and living 
arrangement were not selected from any of the methods. The main predictor variables explaining 
Figure 5-6. Initial classification tree for preference-based Health-Related quality of life 
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the patients’ preference-based HRQoL seems to be BCVA in worse-seeing eye and number of 
ocular conditions.  
5.6.4.6 Model Assessments for Preference-Based Health-Related 
Quality of Life 
The model assessment results for preference-based HRQoL is presented in Table 5-30. The 
model with the lowest MAE for preference-based HRQoL is initial classification tree, with a 
MAE of 0.36. The plausible models are the models with a MAE of 0.38 or less, which only 
included the initial classification tree. However, the initial classification tree is fairly complex 
with 10 predictor variables and may be overfitting, thus this model needs further assessment: 
Preference-based HRQoL = α + β1 (age) + β2 (education) + β3 (use of mobility aid) + β4 
(BCVA in the worse-seeing eye) + β5 (number of comorbidities) + β6 (number of ocular 
conditions) + β7 (number of ocular procedures) + β8 (glaucoma stage) + β9 (time since 
diagnosis) + β10 (initial treatment) 
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Table 5-1. Demographic characteristics of the study population (N = 250) 
Demographic Variables Mean (SD) or Number of Patients (%) 
Age (years) 72.9 (10.2) 
Race  
   Caucasian 199 (79.6) 
   East Asian 3 (1.2) 
   Black 4 (1.6) 
   First Nations 3 (1.2) 
   Other 41 (16.4) 
Income  
   Less than $25 000 87 (37.5) 
   $25 000 to $50 000 73 (31.5) 
   Greater than $50 000 72 (31.0) 
Education  
   Completed high school or less 122 (48.8) 
   Completed more than high school 128 (51.2) 
Living Arrangement  
   Home alone 73 (29.2) 
   Home with others 173 (69.2) 
   Nursing/Retirement home 4 (1.6) 
Use of Mobility Aid  
   Does not use mobility aid 222 (88.8) 
   Uses mobility aid 28 (11.2) 
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Table 5-2. Clinical characteristics of the study population (N = 250) 
Clinical Variables Mean (SD) or Number of Patients (%) 
Best Corrected Visual Acuity  
   Mild visual acuity loss 181 (72.4) 
   Moderate visual acuity loss 37 (14.8) 
   Legal blindness 32 (12.8) 
Number of Comorbidities 1.6 (1.4) 
Number of Ocular Conditions  2.1 (1.1) 
Number of Ocular Procedures 1.1 (1.0) 
Glaucoma Stage   
   Suspect 82 (32.8) 
   Early 65 (26.0) 
   Moderate 65 (26.0) 
   Severe 38 (15.2) 
Time Since Diagnosis (months) 100.7 (74.5) 
Initial Treatment  
   Medication 180 (72.0) 
   Selective Laser Trabeculoplasty 43 (17.2) 
   No initial treatment  27 (10.8) 
 
Table 5-3. Pre- and post-imputed income values 
Missing Variable Pre-imputed income values 
Number of patients (%) 
Post-imputed income values 
Number of patients (%) 
Income   
   Less than $25 000 87 (37.5) 99 (39.6) 
   $25 000 to $50 000 73 (31.5) 75 (30.0) 
   Greater than $50 000 72 (31.0) 76 (30.4) 
 N = 232 N = 250 
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Table 5-4. Pearson correlation coefficient for the association between pairs of continuous 
predictor variables 
 Age Number of 
Comorbidities 
Number of 
Ocular 
Conditions 
Number of 
Ocular 
Procedures 
Time 
Since 
Diagnosis 
Age 1.00     
Number of 
Comorbidities 
0.16 1.00    
Number of 
Ocular 
Conditions  
0.02 -0.01 1.00   
Number of 
Ocular 
Procedures 
0.26 0.03 0.16 1.00  
Time Since 
Diagnosis 
0.004 0.05 0.07 0.21 1.00 
 
Table 5-5. Chi-square tests (p-value) for the association between pairs of categorical 
predictor variables 
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Income   0.49 0.13 0.05 0.22 0.62 0.96 
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    0.68 0.84 0.46 0.81 
Use of Mobility Aid      0.02 0.79 0.56 
Best Corrected 
Visual Acuity  
      0.002 0.52 
Glaucoma Stage         <0.0001 
Initial Treatment         
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Table 5-6. Results of associations between continuous and categorical predictor variables 
Variable 
 
Age 
 
 
p-value 
mean (SD) 
Number of 
Comorbidities 
 
p-value 
mean (SD) 
Number of 
Ocular 
Conditions 
p-value 
mean (SD) 
Number of 
Ocular 
Procedures 
p-value 
mean (SD) 
Time Since 
Diagnosis 
 
p-value 
mean (SD) 
Sex  0.97 0.01 0.08 0.89 0.13 
   Female 72.97 (9.6) 1.77 (1.4) 2.05 (1.0) 1.06 (1.0) 94.88 (73.6) 
   Male 72.92 (11.1) 1.33 (1.3) 2.29 (1.2) 1.08 (1.1) 109.61 (75.5) 
Income 0.03 0.75 0.46 0.85 0.88 
   Less than $25 000 75.01 (10.0) 1.62 (1.3) 2.19 (1.3) 1.11 (0.9) 98.54 (70.8) 
   $25 000 to $50 000 71.15 (9.2) 1.67 (1.6) 2.01 (0.9) 1.05 (1.0) 100.17 (71.6) 
   Greater than $50 000 72.04 (11.1) 1.50 (1.4) 2.21 (1.0) 1.03 (1.1) 104.28 (82.5) 
Education 0.15 0.33 0.96 0.83 0.11 
   Completed high school or less 73.89 (10.7) 1.51 (1.4) 2.15 (1.1) 1.08 (1.0) 93.09 (68.5) 
   Completed more than high school 72.05 (9.8) 1.68 (1.4) 2.14 (1.1) 1.05 (1.0) 108.09 (79.5) 
Living Arrangement 0.0003 0.94 0.92 0.67 0.91 
   Home alone 76.82 (9.6) 1.63 (1.3) 2.18 (1.1) 1.14 (1.0) 101.77 (65.9) 
   Home with others 71.22 (9.8) 1.57 (1.4) 2.13 (1.1) 1.05 (1.0) 100.71 (78.0) 
   Nursing/Retirement home 77.00 (18.7) 1.75 (1.3) 2.00 (1.2) 0.75 (1.0) 85.50 (89.6) 
Use of Mobility Aid <0.0001 0.23 0.20 0.31 0.50 
   Does not use mobility aid 71.98 (10.1) 1.56 (1.4) 2.11 (1.1) 1.05 (1.0) 99.63 (74.7) 
   Uses mobility aid 80.61 (8.0) 1.89 (1.5) 2.39 (1.2) 1.25 (0.9) 109.82 (74.1) 
Best Corrected Visual Acuity 0.03 0.36 0.006 0.17 0.16 
   Mild visual acuity loss 71.90 (10.5) 1.61 (1.4) 2.01 (1.0) 0.99 (1.0) 100.60 (71.3) 
   Moderate visual acuity loss 76.30 (9.4) 1.78 (1.2) 2.43 (1.4) 1.24 (1.0) 85.30 (66.0) 
   Legal blindness 75.03 (8.3) 1.31 (1.5) 2.56 (1.1) 1.28 (1.2) 119.63 (96.8) 
Glaucoma Stage  0.0009 0.47 0.97 0.04 0.07 
   Suspect 69.45 (11.1) 1.59 (1.3) 2.15 (1.1) 0.84 (0.8) 83.24 (63.5) 
   Early 75.23 (9.5) 1.72 (1.6) 2.17 (1.1) 1.26 (1.1) 106.55 (94.2) 
   Moderate 73.35 (8.5) 1.66 (1.4) 2.09 (1.0) 1.03 (1.0) 109.23 (63.5) 
   Severe 75.90 (10.4) 1.23 (1.2) 2.18 (1.2) 1.29 (1.2) 114.24 (72.3) 
Initial Treatment 0.17 0.12 0.19 0.001 0.0002 
   Medication 73.57 (10.1) 1.50 (1.4) 2.22 (1.1) 1.21 (1.1) 111.50 (77.3) 
   Selective Laser Trabeculoplasty 72.40 (9.2) 1.70 (1.6) 1.88 (1.1) 0.67 (0.8) 86.54 (58.6) 
   No initial treatment  69.70 (12.3) 2.07 (1.1) 2.07 (1.0) 0.74 (0.8) 51.93 (54.2) 
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Table 5-7. Unadjusted effects of demographic variables with social support and community 
integration 
Demographic Variables Coefficient P-value 
Age (years) -0.17 <0.0001 
Sex   <0.0001 
   Female Ref  
   Male -3.18 <0.0001 
Income  <0.0001 
   Less than $25 000 Ref  
   $25 000 to $50 000 2.17 0.005 
   Greater than $50 000 2.95 <0.0001 
Education  0.62 
   Completed high school or less Ref  
   Completed more than high school 0.18 0.78 
Living Arrangement  <0.0001 
   Home alone Ref  
   Home with others -1.97 0.004 
   Nursing/Retirement home -9.26 <0.0001 
Use of Mobility Aid  <0.0001 
   Does not use mobility aid Ref  
   Uses mobility aid -4.96 <0.0001 
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Table 5-8. Unadjusted effects of clinical variables with social support and community 
integration 
Clinical Variables Coefficient P-Value 
Best Corrected Visual Acuity  0.25 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss -2.23 0.01 
   Legal blindness -1.60 0.09 
Number of Comorbidities -0.08 0.74 
Number of Ocular Conditions  -0.07 0.82 
Number of Ocular Procedures -0.33 0.29 
Glaucoma Stage   0.74 
   Suspect Ref  
   Early -1.08 0.19 
   Moderate -0.50 0.54 
   Severe -1.19 0.23 
Time Since Diagnosis (months) 0.0002 0.96 
Initial Treatment  0.44 
   Medication Ref  
   Selective Laser Trabeculoplasty 0.39 0.65 
   No initial treatment  1.67 0.11 
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Table 5-9. Adjusted effects for social support and community integration 
Variables Coefficient P-value 
Age (years) -0.15 <0.0001 
Sex   <0.0001 
   Female Ref  
   Male -3.28 <0.0001 
Income  <0.0001 
   Less than $25 000 Ref  
   $25 000 to $50 000 1.34 0.04 
   Greater than $50 000 3.07 <0.0001 
Education  0.76 
   Completed high school or less Ref  
   Completed more than high school 0.05 0.92 
Living Arrangement  <0.0001 
   Home alone Ref  
   Home with others -2.58 <0.0001 
   Nursing/Retirement home -7.92 <0.0001 
Use of Mobility Aid  0.003 
   Does not use mobility aid Ref  
   Uses mobility aid -2.63 0.003 
Best Corrected Visual Acuity  0.15 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss -1.59 0.04 
   Legal blindness -0.76 0.35 
Number of Comorbidities -0.04 0.83 
Number of Ocular Conditions  0.22 0.37 
Number of Ocular Procedures 0.04 0.89 
Glaucoma Stage   0.22 
   Suspect Ref  
   Early 0.54 0.45 
   Moderate 0.42 0.56 
   Severe 1.34 0.13 
Time Since Diagnosis (months) 0.002 0.58 
Initial Treatment  0.09 
   Medication Ref  
   Selective Laser Trabeculoplasty 0.50 0.49 
   No initial treatment  1.41 0.13 
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Table 5-10. Stepwise regression analysis for social support and community integration 
Model ID Eliminated Variable AIC 
1 (initial)  706.19 
2 Glaucoma Stage  702.25 
3 Initial Treatment 699.72 
4 Number of Comorbidities 697.72 
5 Education 695.73 
6 Time Since Diagnosis 693.83 
7 Number of Ocular Procedures 692.05 
8 Number of Ocular Conditions 690.99 
9 Best Corrected Visual Acuity 690.61 
 
Table 5-11. Variable selection for social support and community integration 
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Age  X X X X X 
Sex X X X X X 
Income X X X X  
Education X     
Living Arrangement X X X X  
Use of Mobility Aid X X X X X 
BCVA in Worse-Seeing Eye X   X  
No. of Comorbidities X     
No. of Ocular Conditions X     
No. of Ocular Procedures X     
Glaucoma Stage X   X  
Time Since Diagnosis X   X  
Initial Treatment X     
No. of Selected Variables 13 5 5 8 3 
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Table 5-12. Model assessments from leave-one-out cross validation for social support and 
community integration models 
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Mean Absolute Error  3.99 3.32 3.23 3.21 3.87 3.90 
Standard Error 0.19 0.16 0.15 0.16 0.20 0.19 
Standard Deviation 3.02 2.52 2.40 2.45 3.11 3.02 
 
Table 5-13. Unadjusted effects of demographic variables for the presence of depressive 
symptoms 
Demographic Variables Odds Ratio P-value 
Age (years) 0.99 0.51 
Sex   0.31 
   Female Ref  
   Male 0.52 0.05 
Income  0.04 
   Less than $25 000 Ref  
   $25 000 to $50 000 0.69 0.32 
   Greater than $50 000 0.43 0.04 
Education  <0.0001 
   Completed high school or less Ref  
   Completed more than high school 0.50 0.03 
Living Arrangement  0.04 
   Home alone Ref  
   Home with others 0.58 0.10 
   Nursing/Retirement home 2.65 0.35 
Use of Mobility Aid  <0.0001 
   Does not use mobility aid Ref  
   Uses mobility aid 3.31 0.004 
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Table 5-14. Unadjusted effects of clinical variables for the presence of depressive symptoms 
Clinical Variables Odds Ratio P-Value 
Best Corrected Visual Acuity  0.47 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss 1.76 0.16 
   Legal blindness 1.17 0.74 
Number of Comorbidities 0.91 0.40 
Number of Ocular Conditions  1.14 0.37 
Number of Ocular Procedures 1.00 0.95 
Glaucoma Stage   0.74 
   Suspect Ref  
   Early 0.44 0.06 
   Moderate 0.75 0.46 
   Severe 0.73 0.50 
Time Since Diagnosis (months) 1.00 0.70 
Initial Treatment  <0.0001 
   Medication Ref  
   Selective Laser Trabeculoplasty 2.08 0.06 
   No initial treatment  2.40 0.05 
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Table 5-15. Adjusted effects for the presence of depressive symptoms 
Variables Odds Ratio P-value 
Age (years) 0.97 0.07 
Sex   0.09 
   Female Ref  
   Male 0.49 0.08 
Income  0.15 
   Less than $25 000 Ref  
   $25 000 to $50 000 0.82 0.64 
   Greater than $50 000 0.57 0.23 
Education  0.09 
   Completed high school or less Ref  
   Completed more than high school 0.60 0.16 
Living Arrangement  0.41 
   Home alone Ref  
   Home with others 0.59 0.17 
   Nursing/Retirement home 4.68 0.18 
Use of Mobility Aid  0.006 
   Does not use mobility aid Ref  
   Uses mobility aid 4.37 0.004 
Best Corrected Visual Acuity  0.80 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss 1.81 0.23 
   Legal blindness 0.83 0.73 
Number of Comorbidities 0.83 0.18 
Number of Ocular Conditions  1.20 0.26 
Number of Ocular Procedures 1.13 0.52 
Glaucoma Stage   0.71 
   Suspect Ref  
   Early 0.60 0.31 
   Moderate 1.01 0.99 
   Severe 1.09 0.89 
Time Since Diagnosis (months) 1.00 0.15 
Initial Treatment  0.01 
   Medication Ref  
   Selective Laser Trabeculoplasty 3.52 0.007 
   No initial treatment  3.24 0.046 
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Table 5-16. Stepwise regression for the presence of depressive symptoms 
Model ID Eliminated Variable AIC 
1 (initial) None 258.39 
2 Glaucoma Stage 253.84 
3 Income 251.44 
4 Number of Ocular Procedures 249.69 
5 Best Corrected Visual Acuity 248.03 
6 Number of Ocular Conditions  247.71 
 
Table 5-17. Variable selection results for presence of depressive symptoms 
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BCVA in Worse-Seeing Eye X     
No. of Comorbidities X  X X  
No. of Ocular Conditions X     
No. of Ocular Procedures X     
Glaucoma Stage X     
Time Since Diagnosis X  X X  
Initial Treatment X X X X  
No. of Selected Variables 13 2 8 7 0 
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Table 5-18. Model assessments from leave-one-out cross validation for presence of 
depressive symptoms 
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Mean Absolute Error  0.34 0.31 0.32 0.30 0.32 0.34 
Standard Error 0.02 0.02 0.02 0.02 0.02 0.02 
Standard Deviation 0.24 0.27 0.25 0.26 0.30 0.24 
 
Table 5-19. Unadjusted effects of demographic variables for vision-related quality of life 
Demographic Variables Coefficient P-value 
Age (years) -0.07 0.35 
Sex   0.88 
   Female Ref  
   Male 0.08 0.96 
Income  0.006 
   Less than $25 000 Ref  
   $25 000 to $50 000 2.28 0.23 
   Greater than $50 000 5.19 0.006 
Education  0.114 
   Completed high school or less Ref  
   Completed more than high school 1.58 0.31 
Living Arrangement  0.12 
   Home alone Ref  
   Home with others -0.58 0.73 
   Nursing/Retirement home -23.23 <0.0001 
Use of Mobility Aid  <0.0001 
   Does not use mobility aid Ref  
   Uses mobility aid -11.49 <0.0001 
 
  
 
 
86 
Table 5-20. Unadjusted effects of clinical variables for vision-related quality of life 
Clinical Variables Coefficient P-Value 
Best Corrected Visual Acuity  <0.0001 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss -9.00 <0.0001 
   Legal blindness -18.44 <0.0001 
Number of Comorbidities 0.43 0.45 
Number of Ocular Conditions  -2.05 0.004 
Number of Ocular Procedures -0.59 0.45 
Glaucoma Stage   0.225 
   Suspect Ref  
   Early 1.56 0.45 
   Moderate 0.59 0.77 
   Severe -3.61 0.14 
Time Since Diagnosis (months) 0.006 0.60 
Initial Treatment  0.36 
   Medication Ref  
   Selective Laser Trabeculoplasty 0.46 0.83 
   No initial treatment  -2.86 0.26 
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Table 5-21. Adjusted effects for vision-related quality of life 
Variables Coefficient P-value 
Age (years) 0.07 0.33 
Sex   0.45 
   Female Ref  
   Male 1.04 0.45 
Income  0.01 
   Less than $25 000 Ref  
   $25 000 to $50 000 0.87 0.59 
   Greater than $50 000 3.99 0.02 
Education  0.64 
   Completed high school or less Ref  
   Completed more than high school 0.40 0.76 
Living Arrangement  0.03 
   Home alone Ref  
   Home with others -1.29 0.38 
   Nursing/Retirement home -22.49 <0.0001 
Use of Mobility Aid  <0.0001 
   Does not use mobility aid Ref  
   Uses mobility aid -7.62 <0.0001 
Best Corrected Visual Acuity  <0.0001 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss -8.20 <0.0001 
   Legal blindness -17.03 <0.0001 
Number of Comorbidities 0.44 0.36 
Number of Ocular Conditions  -1.02 0.09 
Number of Ocular Procedures -0.27 0.67 
Glaucoma Stage   0.88 
   Suspect Ref  
   Early 1.13 0.52 
   Moderate 0.16 0.93 
   Severe 0.99 0.65 
Time Since Diagnosis (months) 0.006 0.50 
Initial Treatment  0.20 
   Medication Ref  
   Selective Laser Trabeculoplasty -0.64 0.72 
   No initial treatment  -2.55 0.27 
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Table 5-22. Stepwise regression analysis for vision-related quality of life 
Model ID Eliminated Variable AIC 
1 (initial) None 1167.55 
2 Glaucoma Stage 1162.04 
3 Initial Treatment 1159.97 
4 Number of Ocular Procedures 1157.98 
5 Education 1156.01 
6 Number of Comorbidities 1154.71 
7 Sex 1153.45 
8 Time Since Diagnosis 1153.03 
9 Age 1152.89 
 
Table 5-23. Variable selection for vision-related quality of life 
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Education X     
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Use of Mobility Aid X X X X  
BCVA in Worse-Seeing Eye X X X X X 
No. of Comorbidities X     
No. of Ocular Conditions X  X   
No. of Ocular Procedures X     
Glaucoma Stage X   X  
Time Since Diagnosis X     
Initial Treatment X     
No. of Selected Variables 13 4 5 5 1 
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Table 5-24. Model assessments from leave-one-out cross validation for vision-related 
quality of life 
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Mean Absolute Error  7.73 7.23 6.86 6.95 7.25 6.77 
Standard Error 0.61 0.53 0.52 0.51 0.58 0.56 
Standard Deviation 9.69 8.32 8.14 8.07 9.12 8.83 
 
 
Table 5-25. Unadjusted effects of demographic variables with preference-based HRQoL 
Demographic Variables Odds Ratio P-value 
Age (years) 0.98 0.96 
Sex   0.96 
   Female Ref  
   Male 1.32 0.33 
Income  0.42 
   Less than $25 000 Ref  
   $25 000 to $50 000 0.75 0.40 
   Greater than $50 000 0.76 0.44 
Education  <0.0001 
   Completed high school or less Ref  
   Completed more than high school 1.54 0.13 
Living Arrangement  0.23 
   Home alone Ref  
   Home with others 1.58 0.16 
   Nursing/Retirement home 1.10 0.94 
Use of Mobility Aid  0.83 
   Does not use mobility aid Ref  
   Uses mobility aid 0.62 0.32 
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Table 5-26. Unadjusted effects of clinical variables with preference-based HRQoL 
Clinical Variables Coefficient P-Value 
Best Corrected Visual Acuity  0.22 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss 1.70 0.17 
   Legal blindness 2.81 0.009 
Number of Comorbidities 0.87 0.19 
Number of Ocular Conditions  1.37 0.02 
Number of Ocular Procedures 1.01 0.97 
Glaucoma Stage   0.16 
   Suspect Ref  
   Early 1.00 0.98 
   Moderate 1.20 0.61 
   Severe 1.03 0.95 
Time Since Diagnosis (months) 1.00 0.78 
Initial Treatment  0.27 
   Medication Ref  
   Selective Laser Trabeculoplasty 1.72  
   No initial treatment  0.97 0.95 
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Table 5-27. Adjusted effects for preference-based HRQoL 
Variables Odds Ratio P-value 
Age (years) 0.98 0.28 
Sex   0.65 
   Female Ref  
   Male 1.14 0.69 
Income  0.24 
   Less than $25 000 Ref  
   $25 000 to $50 000 0.72 0.40 
   Greater than $50 000 0.64 0.28 
Education  0.20 
   Completed high school or less Ref  
   Completed more than high school 1.50 0.19 
Living Arrangement  0.32 
   Home alone Ref  
   Home with others 1.53 0.24 
   Nursing/Retirement home 1.30 0.84 
Use of Mobility Aid  0.19 
   Does not use mobility aid Ref  
   Uses mobility aid 0.48 0.20 
Best Corrected Visual Acuity  0.01 
   Mild visual acuity loss Ref  
   Moderate visual acuity loss 2.11 0.09 
   Legal blindness 3.10 0.01 
Number of Comorbidities 0.88 0.27 
Number of Ocular Conditions  1.35 0.04 
Number of Ocular Procedures 1.02 0.91 
Glaucoma Stage   0.83 
   Suspect Ref  
   Early 1.09 0.85 
   Moderate 1.35 0.46 
   Severe 0.90 0.84 
Time Since Diagnosis (months) 1.00 0.95 
Initial Treatment  0.39 
   Medication Ref  
   Selective Laser Trabeculoplasty 1.98 0.09 
   No initial treatment  1.19 0.76 
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Table 5-28. Stepwise regression analysis for preference-based HRQoL 
Model ID Eliminated Variable AIC 
1 (initial) None 312.88 
2 Glaucoma Stage 307.74 
3 Income 305.19 
4 Living Arrangement 302.46 
5 Time Since Diagnosis 300.46 
6 Number of Ocular Procedures 298.47 
7 Sex 296.56 
8 Use of Mobility Aid 295.64 
9 Number of Comorbidities 295.11 
10 Initial Treatment 294.68 
 
Table 5-29. Variable selection results for predicting preference-based HRQoL 
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Age  X  X X  
Sex X     
Income X     
Education X  X X  
Living Arrangement X     
Use of Mobility Aid X   X  
BCVA in Worse-Seeing Eye X X X X  
No. of Comorbidities X   X  
No. of Ocular Conditions X X X X  
No. of Ocular Procedures X   X  
Glaucoma Stage X   X  
Time Since Diagnosis X   X  
Initial Treatment X   X  
No. of Selected Variables 13 2 4 10 0 
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Table 5-30. Model assessments from leave-one-out cross validation for preference-based 
HRQoL 
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Mean Absolute Error  0.42 0.41 0.41 0.40 0.36 0.42 
Standard Error 0.01 0.02 0.01 0.01 0.02 0.01 
Standard Deviation 0.19 0.24 0.21 0.22 0.31 0.19 
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Chapter 6  
 
6 Discussion 
This chapter begins with a statement of the overall goal of our research study (Section 6.1). 
Section 6.2 presents a summary of the study results. Following is the interpretation of the study 
results coinciding with each study objective (Section 6.3).  Next, the strengths and limitations 
(Section 6.4) of the study are presented. The future directions are discussed in Section 6.5. 
Lastly, the conclusions are presented in Section 6.6. 
6.1 Overall Goal of Study 
The overall goal of our research study was to identify predictor variables that are most strongly 
associated with four PROs: social support and community integration; presence of depressive 
symptoms; VRQoL; and preference-based HRQoL. This was accomplished through rigorous 
methodologies including inferential statistics and machine learning techniques. Identifying 
important drivers of PROs can support ophthalmologists to better manage and treat glaucoma 
patients. In addition to the clinical importance of this study, the proposed methodology can be 
used for future research. Our research study highlights rigorous methodology that goes beyond 
interpreting results based on statistical significance.  
6.2 Summary of Study Results 
Overall, the patients in our study are satisfied with their care and treatment. Patients reported low 
depressive symptoms, moderate social support and community integration, high VRQoL and 
preference-based HRQoL.  
The patients were spread across a wide age range between 40 and 93 years of age, with a mean 
age of about 73 years old. Forty percent of the patients had an income lower than $25 000, and 
about 49% completed high school or less, thus there was not much variability in income and 
education levels. In terms of their clinical outcomes, about 72% experienced mild visual acuity 
loss; thus, their visual functioning was not greatly debilitated. The time since diagnosis ranged 
widely from one month to about 42 years, with an average time of about eight years. On average, 
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the patients had about two other comorbidities and two other ocular conditions (excluding 
glaucoma) and had about one prior ocular procedure performed.   
In our patient population, use of mobility aids was a common predictor variable identified for 
three of the PROs: social support and community integration, presence of depressive symptoms 
and VRQoL. BCVA in the worse-seeing eye was a common predictor variable identified for 
three of the PROs: social support and community integration, VRQoL and preference-based 
HRQoL. Income and living arrangements were common predictor variables identified for social 
support and community integration and VRQoL. Thus, across all PROs, clinical predictors that 
are routinely collected (BCVA) during a typical comprehensive eye exam did not seem to have 
as much of an influence as the variables that were not typically collected (use of mobility aids, 
income and living arrangements).  
Understanding the predictor variables of important PROs may help ophthalmologists identify 
patients who are at a greater risk or who would most benefit from services that could improve 
their disease management. For instance, if an ophthalmologist can identify a patient who may 
need social support and who is unable to perform activities of daily living due to their glaucoma 
progression, then ophthalmologists would consider referral of these patients for necessary 
support and services. The developed models could help ophthalmologists be more aware of their 
patients’ ocular and non-ocular needs. This is particularly important for this patient population, 
since our study findings suggest that many of the factors that are driving PROs are not clinical. 
Our results indicate that ensuring that the patient has an adequate support system and access to 
services to help them adapt to loss of their visual functioning could have a larger impact on 
improving PROs than providing clinical management alone. In addition, the results obtained can 
be a guide for future ophthalmic research in assessing predictor variables of important PROs. 
The developed models (refer to Section 5.6) may be a useful tool for ophthalmologists, 
researchers, health economists and policy makers for better tailored glaucoma management.  
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6.3 Interpretation of Study Results 
6.3.1 Social Support and Community Integration  
The first objective of our research study was to assess social support and community integration 
as measured by the Community Integration Questionnaire (CIQ), and determine which clinical 
and/or demographic variables impact the overall score. 
Patients in our research study scored moderately high on the CIQ scale, with an average score of 
17.9±5.0, representing moderate social support and community integration. In comparison, Hirsh 
et al. (2011) conducted a cross-sectional study which included 751 adults with different physical 
disabilities (spinal cord injury, multiple sclerosis, limb loss and muscular dystrophy), and 
reported, on average, a similar total score of 17.1±5.1101. However, in comparison to our research 
study, the participants from Hirsh et al.’s (2011) study were, on average, younger (50.9±13.5 
years, range: 18 to 91) and a greater number had completed more than high school (84%)101. 
Singh et al. (2015) conducted a study among 30 geriatric patients and reported a total score of 
22.9±5.0, which is slightly higher than our study population109. On average, the study population 
of Singh et al. (2015) was similar in age (73 years; range: 65 to 90) to our study population109. 
However, the proportion of patients who were over 75 years of age was less (33%) than the 
proportion in our study population (41%). Patients over 75 years of age may be less able to 
participate in the community and lack social support than the younger patients. To our 
knowledge, ophthalmology research and ophthalmic practice do not assess the patient’s social 
support and community integration needs. 
We found age, sex, income, living arrangement and use of mobility aids to be the most 
promising predictor variables of social support and community integration. Specifically, 
increasing age, being a male, and living at home with others or in a nursing/retirement home, 
predicted lower social support and community integration. Income above $25 000 was predictive 
of greater social support and community integration. Considering the absolute values of the 
regression coefficients, living in a nursing or retirement home (b = -7.92) and having an income 
greater than $50 000 (b = 3.07) are expected to have the strongest effects on the patient’s level of 
social support and community integration.  However, among our study population only 1.6% (n 
= 4) were living in a nursing or retirement home. Our findings suggest that these patients are less 
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functional within their community and need the support of others (i.e., spouse, family or 
caregiver). For instance, patients who use mobility aids may require assistance to perform their 
daily activities such as shopping and going to visit family and friends. To be more confident in 
the results, a larger representation of patients living in a nursing or retirement home would be 
required.  
Overall, the moderate level of social support and community integration among our study 
population was not surprising, since only a small proportion of our population had severe 
glaucoma. This may reflect the practice pattern of the ophthalmologist who manages patients at 
all stages of glaucoma and institutes care for preventing their disease from becoming advanced. 
Thus, inclusion of more equal proportion of patients within each glaucoma stage and living 
arrangement category may strengthen some associations.  
6.3.2 Presence of Depressive Symptoms  
The second objective of our research study was to assess the presence of depressive symptoms as 
measured by the Patient Health Questionnaire-9 (PHQ-9), and determine which clinical and/or 
demographic variables impact the presence or absence of depressive symptoms. 
Depression has been reported to be higher in individuals with chronic illnesses and among 
elderly people. Glaucoma is a chronic ocular disease that is most prevalent among elderly people 
and due to the progression of vision loss, it is likely that patients experience depressive 
symptoms182. Among our study population, about 21% reported having depressive symptoms. 
Simon et al. (2008) used the Geriatric Depression Scale-15 and found that depression was more 
prevalent with increasing glaucoma severity113. Although the majority of our study population 
did not present with depressive symptoms, it is important to note that only about 15% of the 
patients were diagnosed with severe glaucoma. Thus, having a study population that included a 
greater number of patients with advanced disease may provide more accurate effect estimates. 
Assessing depressive symptoms among glaucoma patients and identifying associated factors are 
still important in providing better care to improve the patients’ HRQoL as knowledge of the 
diagnosis itself and its treatment may be a source of depression for some patients.      
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Our results suggest that use of mobility aids and initial treatment were the most promising 
predictor variables of the presence of depressive symptoms. Patients who used mobility aids 
were about four times more likely to report the presence of depressive symptoms than patients 
who did not use mobility aids. It was predicted that medication use would be more burdensome 
for the patient, due to the inconvenience of the medication regimen and well established reports 
of poor patient compliance. However, our study results revealed that patients whose initial 
treatment was selective laser trabeculoplasty (SLT), or who had no initiations of treatment, were 
both more than about three times more likely to report having depressive symptoms compared to 
patients whose initial treatment was medication. This study finding was surprising for a number 
of reasons. Published studies have shown that both SLT and medication are known to be 
effective in lowering IOP in patients, and literature supports SLT as an effective initial treatment 
thus preventing, or delaying, the need for medical therapy183.  Possible reasons for this finding 
include: patients who did not receive medical management for glaucoma had, by chance, other 
underlying causes for depressive symptoms; the patients who did not receive medical 
management had protective factors against depression; patients whose initial treatment was 
medication were more secure in the perception that they were actively participating in their 
disease management; the need for chronic medical therapy is not as burdensome for some 
patients as published studies have suggested; and lastly, a larger, more diverse sample size may 
be required to accurately report on this finding. 
To our knowledge no previous studies among glaucoma patients have used the PHQ-9 to assess 
depressive symptoms. However, Wilson et al. (2002) did conduct a study using the Center for 
Epidemiologic Studies Depression Scale and Composite International Diagnostic Interview Short 
Form, among patients with glaucoma and without glaucoma182. Wilson et al., (2002) concluded 
that patients with glaucoma did not report being more depressed than patients without 
glaucoma182. On the other hand, a multicentre prospective case-control study reported that 
patients with POAG had a higher prevalence of depression than the sex- and age-matched control 
group92. In addition, a study conducted among glaucoma patients in a Turkish population, found 
that the presence of depression was associated with lower QoL scores111. Furthermore, a study 
that used the Hamilton Depression Rating Scale among Singaporean patients with glaucoma, 
found that 30% of their study population had depression, and found that female sex and 
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worsening clinical outcomes of the eye were significant factors associated with depression16. 
Supporting our study findings, Wilson et al. (2002) reported that clinical outcome measures such 
as visual acuity, visual field severity and use of topical medication were not strongly predictive 
of depression among glaucoma patients182.    
6.3.3 Vision-related Quality of Life 
The third objective of our study was to assess vision-related quality of life (VRQoL) as measured 
by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), and determine 
which clinical and/or demographic variables impacted the composite score, in glaucoma suspects 
and patients diagnosed with glaucoma. 
The VRQoL of our study population was reported to be high, with a composite score of 
88.7±12.4. As previously stated, there were only 15% of patients who were diagnosed with 
severe glaucoma in our study population. In contrast, a study conducted among a Turkish 
population, reported a lower composite score of (66.4±19.3)184. However, the mean age in the 
Turkish population was younger (60.9±14.5 years) and only 9.8% were diagnosed with 
glaucoma; the rest of the patients were diagnosed with either cataract (57.4%), diabetic 
retinopathy (13.2%), age-related macular degeneration (11.4%) or degenerative myopia 
(8.2%)184. Karadeniz et al. (2017) reported a composite score of 86.4±7.0 among glaucoma 
patients and found significant correlation between BCVA and VRQoL185. Although, on average, 
the age of the study population reported by Karadeniz et al. (2017) was younger (64.9±10.5 
years) than the age of our study population, the composite score obtained in both study 
populations were similar. 
Previous studies have assessed the VRQoL of glaucoma patients using the NEI VFQ-25. 
Carreras et al. (2017) found that patients with moderate to severe glaucoma reported significantly 
lower NEI VFQ-25 scores than patients with normal eyes186. Cahill et al. (2005) reported that 
NEI VFQ-25 scores, among a group of patients with low vision,  were negatively correlated with 
increasing age and duration of vision loss187. A study among a Swedish population used a 
Swedish translation of the NEI VFQ-25 to assess VRQoL and concluded that the scores were 
associated with clinical characteristics such as visual acuity and visual field loss and patients 
with no visual impairment scored higher than patients with visual impairment188. Similarly, our 
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results suggest that the best possible predictor variable of VRQoL was BCVA in the worse-
seeing eye. Specifically, the absolute values of the multivariable regression coefficients suggest 
that legal blindness (b = -17.03) and moderate visual acuity loss (b = -8.20) are expected to have 
a larger decrease on VRQoL, compared to patients with mild visual acuity loss. In addition, 
Murata et al. (2015) confirm our results, as they also reported BCVA in the worse-eye as the 
most important variable for VRQoL189. Takahashi et al. (2016) also found significant 
associations between visual function impairment and VRQoL190. In addition, Sun et al. (2016) 
reported that patients with visual defects in the better eye were more likely to have lower 
VRQoL scores191. Thus, vision-specific clinical outcome measures are important predictor 
variables of VRQoL. 
6.3.4 Preference-based Health-Related Quality of Life  
The fourth objective of our research study was to assess the preference-based HRQoL as 
measured by the Time Trade-Off technique (TTO) and determine which clinical and/or 
demographic variables impact the utility values in glaucoma suspects and patients diagnosed 
with glaucoma.  
Among our study population only about 10% had a low visual acuity with low vision reporting 
either counting fingers (CF), hand motion (HM), light perception (LP) or no light perception 
(NLP). Thus, very few patients reported low TTO utility values. Previous studies reported 
associations between preference-based HRQoL and visual acuity. Brown (1999) concluded that 
preference-based HRQoL decreases as the vision in the better-seeing eye decreases87. Brown et 
al. (1999) reported that patients with a poor visual acuity value (i.e., counting fingers) were 
willing to give up more years of their remaining life compared to patients with a better visual 
acuity (i.e., 20/20)123.  
Recall from Section 2.7.4 that utility values are rated on a scale between 0 (death) and 1 (perfect 
health). The utility value reported by our patient population, on average was 0.91. About 71% of 
the patients reported a perfect utility value of 1, meaning that majority of the patients were not 
willing to give up any years of life for perfect vision. This finding may, in part, be due to the 
relatively small number of severe glaucoma patients in the study population (15%). Likewise, 
Jampel et al. (2002) reported a high preference-based HRQoL (utility value = 0.93) among 
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patients diagnosed with glaucoma192. The glaucoma patients in Jampel et al.’s (2002) study were 
similar in age to our study population (71.8±11.2 years) and majority were Caucasian (76%)192.  
A low mean TTO utility value of 0.64 was reported among a group of Indian glaucoma patients, 
representing a poorer preference-based HRQoL96. Another study among a Chinese population 
reported a mean utility value of 0.88124. Since our study population was about 80% Caucasian, 
further investigation would be interesting in a more diverse Canadian population to evaluate the 
effect of race in a country which has access to a universal health care system. 
Aspinall et al. (2008) reported that only 17% of the patients were willing to consider trading their 
remaining years of life for perfect vision125. Among our study population, about 30% were 
willing to consider trading their remaining years of life for perfect vision. Although Aspinall et 
al. (2008) did not include patients with other ocular comorbidities and had a smaller sample size 
(n = 72), similar to our research study, only a minority of patients were willing to trade their 
years of life for perfect vision. 
The results of our study found that the most promising predictor variables of preference-based 
HRQoL were: age, education, use of mobility aids, BCVA in the worse-seeing eye, number of 
comorbidities, number of ocular conditions, number of ocular procedures, glaucoma stage, time 
since diagnosis and initial treatment. To avoid overfitting, the TTO model would benefit from 
further assessment, with a larger population of diverse glaucoma severity groups.  
Similar to our study findings, previous studies reported both clinical and demographic 
associations with preference-based HRQoL. Like our study, Sharma et al. (2000) included 
patients with various ocular conditions and determined that preference-based HRQoL was 
significantly associated with only BCVA in the better-seeing eye138. Kobelt et al. (2006) reported 
that clinical variables such as total visual acuity, visual acuity in the better-seeing eye were 
significantly correlated with preference-based HRQoL and patients with severe damage reported 
poorer HRQoL193. However, very few patients in our study population had severe glaucomatous 
damage.  In addition, to the commonly reported association between preference-based HRQoL 
and visual acuity loss, Gupta et al. (2005) also found significant associations between 
preference-based HRQoL and educational status96. Our study findings also found education to be 
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predictive of preference-based HRQoL. Likewise, Guedes et al. (2014) reported that higher 
education tended to predict higher preference-based HRQoL 150. Zhang et al. (2015) also 
reported that preference-based HRQoL was related to education level and employment status151. 
Contrary to our findings, Brown (1999) found that age, level of education, gender, race, length of 
time of visual loss and number of comorbidities did not significantly affect preference-based 
HRQoL87. Brown (1999) only included patients who had a visual loss of 20/40 or worse, 
whereas in our study included patients with visual loss better than 20/40. 
It is important to note that the mentioned studies only performed multivariable regression 
analysis to determine which variables were associated with preference-based HRQoL, whereas 
our research study performed multivariable regression analysis, stepwise regression by AIC and 
variable selection using CART to identify the most promising predictor variables of preference-
based HRQoL. 
6.3.5 Models for Predicting Patient-Reported Outcomes 
The final objective of this study was to develop models for predicting social support and 
community integration, presence of depressive symptoms, VRQoL and preference-based 
HRQoL based on clinical and/or demographic variables, and validate the resulting models.  
A total of 13 predictor variables were included in the initial model for analysis for each PRO. 
After performing three model selection methods (multivariable regression, stepwise regression 
by AIC, and CART) and assessing the model performance using LOOCV, the most promising 
predictor variables to be included in the final model for each PRO were identified to be the 
following: 
Social support and community integration: age, sex, income, living arrangement and 
use of mobility aids 
Presence of depressive symptoms: use of mobility aids and initial treatment 
Vision-related quality of life: BCVA in the worse-seeing eye 
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Preference-based HRQoL: age, education, use of mobility aids, BCVA in the worse-
seeing eye, number of comorbidities, number of ocular conditions, number of ocular 
procedures, glaucoma stage, time since diagnosis and initial treatment 
Our study findings focus on the methodology used to identify the most promising predictor 
variables of each outcome. Previous studies solely relied on multivariable regression to identify 
significant variables and often conclusions from these research studies were based on 
significance levels. In contrast, our research study presents a novel contribution to the 
methodology using a combination of inferential statistics and machine learning techniques to 
identify the best predictor variables of an outcome. Further, the accuracy of each model was 
determined to provide stronger support for the conclusions. Future research can investigate how 
to best apply and incorporate these study findings into clinical practice guidelines for better 
glaucoma management. This would be a novel utilization of our research as currently very few 
international clinical practice guidelines incorporate evidence on PROs194. We also determined 
the accuracy of each model to provide more support for our conclusions. 
The prediction models permit estimation of the patients’ social support and community 
integration, depressive symptoms, VRQoL and preference-based HRQoL. This can be used to 
allow ophthalmologists to identify which patients who are at high-risk for higher depressive 
symptoms, lower social support and community integration, VRQoL and preference-based 
HRQoL.  
6.4 Study Strengths and Limitations  
One of the strengths of this study is the sample size (n = 250), which was large compared to 
previous studies assessing PROs among glaucoma patients. Another strength is that this study 
included patients with various levels of glaucoma severity, who had a variety of glaucoma 
interventions ranging from observation to surgery, and who had concurrent comorbidities. The 
research also benefited from low levels of missing data, so multiple imputation only needed to be 
performed on one variable. In addition, multiple reliable and valid PRO measurement tools were 
employed. A comprehensive set of PROs, using specific measurement tools as opposed to 
generic ones, allowed capture of precise, disease-specific results.  
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Most of the patients in this study had mild glaucoma as defined by Canadian practice guidelines 
which likely reflects the effectiveness of screening and early intervention in the community and 
practice in which the study was done. Patients with severe glaucoma and those living in a 
nursing or retirement home were under-represented in this population, which may have different 
outcomes if compared to a more advanced disease population.  
Although our study included several types of glaucoma and other ocular conditions, results may 
differ if a subgroup analysis was performed, the latter which would benefit from an even larger 
sample size than the one examined. Also, since we conducted an exploratory analysis, some of 
the identified predictor variables may have associations simply by chance. Although this study 
was unique in utilizing a number of PROs, each is limited by their nature of being subjective and 
variable even among patients with similar clinical characteristics. Finally, we did not capture the 
patient’s knowledge of glaucoma, which may present as a bias when measuring PROs. 
 
6.5 Future Directions 
This study presented proof of principle findings that provide a basis for future investigation. It 
would be ideal to conduct future studies intended to identify predictor variables of PROs that 
employ similar methodology using a combination of inferential statistics, machine learning 
techniques and model assessment. Previous ophthalmic studies rely on multivariable regression 
analysis for their analysis and interpret their results based on statistical significance. However, 
results should be interpreted beyond statistical significance and assess how accurately a model 
will perform. Machine learning techniques can provide a great contribution to ophthalmic 
research and practice by identifying patients at high risk for poor PROs. Further research could 
explore a broader range of demographic and clinical variables, and the role of other PROs among 
glaucoma patients. 
 
Based on the results for the preference-based HRQoL model, where 10 predictor variables were 
identified, recommendations for future research would be to develop a more specific model to 
identify fewer predictor variables. A multicentre study that would allow input from a diverse 
population would be useful to confirm the association of the identified predictor variables in 
other settings. It would also be informative to track temporal changes in PROs, through longer 
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follow-up periods. Therefore, further studies with a larger diverse population stratified by disease 
severity and longer follow-up periods would be required for validation the latter which, however, 
would be limited by the challenges involved in performing long-term, multicentre studies. 
6.6 Conclusion 
As governments are now investing in programs aiming to increase patient input into health care 
decision making, studies and methodologies such as this will have continued and increased 
relevance. Measuring PROs is particularly useful for chronic, progressive diseases such as 
glaucoma as their management and treatment have a greater impact on quality of life when 
compared to acute and curable conditions. The importance has recently increased due to the 
creation of formalized programs by governments which seek direct patient input into health care 
decision making policies. Our research adds to the literature a novel methodology for 
determining predictor variables for important PROs. Our findings highlight that, in the case of 
glaucoma, PROs are mostly influenced by demographic characteristics, rather than clinical 
characteristics.  
The study results support the potential of developing a clinical tool that may allow clinicians to 
identify patients who may benefit from additional support and resources, beyond routine clinical 
care and treatment. Comprehensive and targeted rehabilitative services can be developed to 
target the needs of these patients. Studies such as this may be useful to health care policy makers 
when making decisions on how to best allocate resources directed to patient-centered approaches 
to health care. Although, inherently subjective, patient input into their health care has become a 
priority for a number of countries, including Canada. As this is a relatively recent initiative, 
evidence to guide this process would help ensure the most cost-effective implementation of such 
programs. In the case of glaucoma, it would be important to stress the context, which requires 
research across various ophthalmic practice settings. For instance, patient’s experience can be 
influenced by wait times, the type and location of the health care facility, relationship with the 
ophthalmologist and administrative staff, access to innovations in care, etc. Among our study 
population, the PROs were found to be high, revealing that patients were satisfied with the 
quality of care. Many of the patients expressed their trust in the ophthalmologist, so that they did 
not have to stress about their glaucoma progression. Since the patients in our study were only 
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recruited from one practice, our results may only be generalizable to patients of this 
ophthalmologist, her referral base and the setting in which she practices. Patients with severe 
glaucoma, as well as non-Caucasian patients, were under-represented in this study; thus, these 
results may not be generalizable to other populations and settings. 
The predictive performance of each model is specific to our study population, and would need 
further validation among a diverse population to be generalizable. This would further elucidate 
the practical value of each model. Although we cannot be certain of the exact relationship 
between the predictor variables and each PRO, the methodology in this study provides a solid 
foundation upon which further studies can be done. This happens to coincide at a time in which 
patient-driven health care has become a priority for a number of provincial and international 
governments. 
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Appendix B: Sample size calculation formulas 
 
1. Beta function: n %, # = 6J;+(1 − 6)o;+i6J)  
where B is the normalization constant 
          % and	# are real numbers  
2. Cohen’s f2 effect size for an F-test: j, = Y,1 − Y, 
where Y, is the squared multiple correlation 
3. Error function: _Rj % = 2
p
_;pqi6J)  
where ,
p
 is the normalization factor, defined as the probability density function 
 
4. F-distribution cumulative distribution function: r %; i+, i, = 	 = tuJtuJvtq(i+2 , i,2 )	 
where i+ and i, are the degrees of freedom 
 = is the regularized lower incomplete beta function (w(J;x,y)w(x,y) ) 
5. Non-central F-distribution cumulative distribution function: 
r % i+, i,, l = ((12 l)1z! )_;l,¥1G) 	=( i+ri, + i+r | i+2 + z, i,2 ) 
where i+ and i, are the numerator and denominator degrees of freedom 
l is the non-central parameter 
  F is the Fisher F-value  
  I is the regularized lower incomplete beta function (w(J;x,y)w(x,y) ) 
6. Non-central F-distribution parameter: 
l	 = 	 j,I 
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 where j, is the effect size 
 I  is the sample size 
7. Normal distribution cumulative distribution function: r %;µ, |, = 12 [1 + _Rj	(% − }| 2 )] 
where 	µ  is the mean | is the standard deviation  _Rj is the error function 
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Appendix C. Community Integration Questionnaire (CIQ) 
1. Who usually does the shopping for groceries or 
other necessities in your household? 
o Yourself alone 
o Yourself and someone else 
o Someone else 
2. Who usually prepares meals in your household? o Yourself alone 
o Yourself and someone else 
o Someone else 
3. In your home who usually does the everyday 
housework? 
o Yourself alone 
o Yourself and someone else 
o Someone else 
o Not applicable 
4. Who usually cares for the children in your home? o Yourself alone 
o Yourself and someone else 
o Someone else 
o Not applicable 
5. Who usually plans social arrangements such as 
get-togethers with family and friends? 
o Yourself alone 
o Yourself and someone else 
o Someone else 
6. Who usually looks after your personal finances, 
such as banking or paying bills 
o Yourself alone 
o Yourself and someone else 
o Someone else 
7. Approximately how many times a month do you 
usually participate in shopping outside your 
home? 
o Never 
o 1-4 times 
o 5 or more 
8. Approximately how many times a month do you 
usually participate in leisure activities such as 
movies, sports, restaurants etc. 
o Never 
o 1-4 times 
o 5 or more 
9. Approximately how many times a month do you 
usually visit your friends or relatives? 
o Never 
o 1-4 times 
o 5 or more 
10. When you participate in leisure activities do you 
usually do this alone or with others? 
o Mostly alone 
o Mostly with friends 
o Mostly with family members 
o With a combination of family 
and friends 
11. Do you have a best friend with whom you 
confide? 
o Yes 
o No 
12. How often do you travel outside the home? o Almost every day 
o Almost every week 
o Seldom/never (less than once 
per week) 
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13. Please choose the answer that best corresponds to 
your current (during the past month) work 
situation: 
o Full-time (more than 20 
hours/week) 
o Part-time (less than or equal 
to 20 hours/week) 
o Not working, but actively 
looking for work 
o Not working, not looking for 
work 
o Not applicable (retired, 
disability) 
14. Please choose the answer that best corresponds to 
your current (during the past month) school or 
training program situation: 
o Full-time 
o Part-time 
o Not attending school, or 
training program 
o Not applicable (retired, 
disability) 
15. In the past month, how often did you engage in 
volunteer activities 
o Never 
o 1-4 times 
o 5 or more 
 
*(adapted from: Dijkers, M. (2000). The Community Integration Questionnaire. The Center for 
Outcome Measurement in Brain Injury. http://www.tbims.org/combi/ciq) 
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     Add Columns     +   +   
            Total    
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of the things at home, or get along with other people? 
Not difficult 
at all 
Somewhat 
difficult 
Very 
difficult 
Extremely 
difficult 
    
 
* Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with 
an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or 
distribute 
 
 
 
Over the last 2 weeks, how often have you been 
bothered by any of the following problems? 
Not at 
all 
Several 
Days 
More than 
half the days 
Nearly 
Every 
day 
1.  Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3.  Trouble falling asleep or sleeping too much    0 1 2 3 
4.  Feeling tired or having little energy 0 1 2 3 
5.  Poor appetite or overeating 0 1 2 3 
6.  Feeling bad about yourself- or that you are  
a failure or have let yourself or family down 0 1 2 3 
7.  Trouble concentrating on things, such as reading 
the newspaper or watching television 0 1 2 3 
8.  Moving or speaking so slowly that other people 
could have noticed.  Or the opposite-being so fidgety 
or restless that you have been moving around a lot 
more than usual 
0 1 2 3 
9.  Thoughts that you would be better off dead, or of 
hurting yourself in some way 0 1 2 3 
Appendix D. Patient Health Questionnaire (PHQ-9) 
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Appendix E. National Eye Institute Visual Function Questionnaire – 25 (NEI 
VFQ-25) 
 
PART 1 - GENERAL HEALTH AND VISION 
1. In general, would you say your overall health is: (Circle One) 
Excellent............................... 1 
Very Good............................ 2 
Good...................................... 3 
Fair......................................... 4 
Poor........................................ 5 
 
2. At the present time, would you say your eyesight using both eyes (with glasses or contact 
lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind? 
(Circle One) 
Excellent............................... 1 
Good...................................... 2 
Fair......................................... 3 
Poor........................................ 4 
Very Poor.............................. 5 
Completely Blind................ 6 
3. How much of the time do you worry about your eyesight? (Circle One) 
None of the time............................. 1 
A little of the time........................... 2 
Some of the time............................ 3 
Most of the time.............................. 4 
All of the time?................................ 5 
 
4. How much pain or discomfort have you had in and around your eyes 
(for example, burning, itching, or aching)? Would you say it is: (Circle One) 
None....................................... 1 
Mild......................................... 2 
Moderate............................... 3 
Severe, or............................. 4 
Very severe?........................ 5 
 
PART 2 - DIFFICULTY WITH ACTIVITIES 
The next questions are about how much difficulty, if any, you have doing certain activities 
wearing your glasses or contact lenses if you use them for that activity. 
 
5. How much difficulty do you have reading ordinary print in newspapers? Would you say you 
have: (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
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Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested  
in doing this...................................... 6 
 
6. How much difficulty do you have doing work or hobbies that require you to see well up close, 
such as cooking, sewing, fixing things around the house, or using hand tools? Would you say: 
(Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
7. Because of your eyesight, how much difficulty do you have finding something on a crowded 
shelf? (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
8. How much difficulty do you have reading street signs or the names of stores?(Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this........................... 6 
 
 
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs 
in dim light or at night? (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
10. Because of your eyesight, how much difficulty do you have noticing objects off to the side 
while you are walking along?(Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
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Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
11. Because of your eyesight, how much difficulty do you have seeing how people react to things 
you say? (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
12. Because of your eyesight, how much difficulty do you have picking out and matching your 
own clothes? (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
13. Because of your eyesight, how much difficulty do you have visiting with people in their 
homes, at parties, or in restaurants? (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
14. Because of your eyesight, how much difficulty do you have going out to see movies, plays, 
or sports events? (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
15. Are you currently driving, at least once in a while? (Circle One) 
Yes........................ 1 Skip To Q 15c 
No ......................... 2 
 
15a. IF NO: Have you never driven a car or have you given up driving? (Circle One) 
       Never drove........ 1 Skip To Part 3, Q 17 
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       Gave up............... 2 
 
15b. IF YOU GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some 
other reason, or because of both your eyesight and other reasons? (Circle One) 
Mainly eyesight..................................... 1 Skip To Part 3, Q 17 
Mainly other reasons ........................... 2 Skip To Part 3, Q 17 
Both eyesight and other reasons .... 3 Skip To Part 3, Q 17 
 
15c. IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime 
in familiar places? Would you say you have: (Circle One) 
No difficulty at all................................. 1 
A little difficulty..................................... 2 
Moderate difficulty............................... 3 
Extreme difficulty................................. 4 
 
16. How much difficulty do you have driving at night? Would you say you have: (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
16A. How much difficulty do you have driving in difficult conditions, such as in bad weather, 
during rush hour, on the freeway, or in city traffic? Would you say you have: (Circle One) 
No difficulty at all......................................................... 1 
A little difficulty............................................................. 2 
Moderate difficulty....................................................... 3 
Extreme difficulty......................................................... 4 
Stopped doing this because of your eyesight..... 5 
Stopped doing this for other reasons or not interested in doing this............. 6 
 
PART 3: RESPONSES TO VISION PROBLEMS 
The next questions are about how things you do may be affected by your vision. For each one, 
please circle the number to indicate whether for you the statement is true for you all, most, some, 
a little, or none of the time. (Circle One On Each Line) 
  All of 
the time 
Most of 
the time 
Some 
of the time 
A little 
of the time 
None of 
the time 
17 Do you accomplish less 
than you would like 
because of your vision? 
1 2 3 4 5 
18 Are you limited in how 
long you can work or do 
other activities because 
of your vision? 
1 2 3 4 5 
19 How much does pain or 1 2 3 4 5 
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discomfort in or around 
your eyes, for example, 
burning, itching, or 
aching, keep you from 
doing what you’d like to 
be doing? 
 
 
 
For each of the following statements, please circle the number to indicate whether for you the 
statement is definitely true, mostly true, mostly false, or definitely false for you or you are not 
sure. (Circle One On Each Line) 
  Definitely 
true 
Mostly 
true 
Not 
sure 
Mostly 
false 
Definitely 
false 
20 I stay home most of the time 
because of my eyesight. 1 2 3 4 5 
21 I feel frustrated a lot of the 
time because of my eyesight. 1 2 3 4 5 
22 I have much less control over 
what I do, because of my 
eyesight. 
1 2 3 4 5 
23 Because of my eyesight, I 
have to rely too much on 
what other people tell me 
1 2 3 4 5 
24 I need a lot of help from others 
because of my eyesight. 1 2 3 4 5 
25 I worry about doing things that 
will embarrass myself or others, 
because of my eyesight. 
1 2 3 4 5 
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Appendix F. Time Trade-Off (TTO) 
 
How many years do you expect to live? __________________years 
 
Suppose there was a new technology that could restore your eyesight to perfectly normal in 
both eyes. The technology always works but decreases the length of time you live.  
 
What is the maximum number of years, if any, that you would be willing to give up if you 
could receive this technology and have perfect vision for your remaining years? 
 
                                                                 ___________________years 
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